It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.
The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.
Zacks Premium also includes the Zacks Style Scores.
What are the Zacks Style Scores? The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.
Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value ScoreFinding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.
Growth ScoreWhile good value is important, growth investors are more focused on a company's financial strength and health, and its future outlook. The Growth Style Score takes projected and historic earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth.
Momentum ScoreMomentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.
VGM ScoreIf you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.
#1 (Strong Buy) stocks have produced an unmatched +23.8% average annual return since 1988, which is more than double the S&P 500's performance over the same time frame. However, the Zacks Rank examines a ton of stocks, and there can be more than 200 companies with a Strong Buy rank, and another 600 with a #2 (Buy) rank, on any given day.
With more than 800 top-rated stocks to choose from, it can certainly feel overwhelming to pick the ones that are right for you and your investing journey.
That's where the Style Scores come in.
You want to make sure you're buying stocks with the highest likelihood of success, and to do that, you'll need to pick stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you like a stock that only has a #3 (Hold) rank, it should also have Scores of A or B to guarantee as much upside potential as possible.
The direction of a stock's earnings estimate revisions should always be a key factor when choosing which stocks to buy, since the Scores were created to work together with the Zacks Rank.
Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Medpace (MEDP - Free Report) Medpace Holdings, Inc. is a global clinical contract research organization (CRO) delivering full-service Phase I-IV drug and device development support, including protocol and project management, regulatory affairs, clinical monitoring, data management/analysis, pharmacovigilance, submission support, and specialized services such as bioanalytical labs and medical imaging. The company is headquartered in Cincinnati, OH, and employed approximately 6,500 people across 46 countries as of June 30, 2026.
MEDP is a #3 (Hold) on the Zacks Rank, with a VGM Score of B.
Additionally, the company could be a top pick for growth investors. MEDP has a Growth Style Score of A, forecasting year-over-year earnings growth of 14.6% for the current fiscal year.
Five analysts revised their earnings estimate upwards in the last 60 days for fiscal 2026. The Zacks Consensus Estimate has increased $0.47 to $17.51 per share. MEDP boasts an average earnings surprise of +10.2%.
With a solid Zacks Rank and top-tier Growth and VGM Style Scores, MEDP should be on investors' short list.
Bank of New York Mellon Corp bought a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 146,588 shares of the company’s stock, valued at approximately $77,632,000. Bank of New York Mellon Corp owned 0.53% of Medpace as of its most recent SEC filing.
Several other hedge funds have also recently added to or reduced their stakes in MEDP. Focus Partners Advisor Solutions LLC acquired a new stake in Medpace during the second quarter valued at approximately $1,685,000. State of Wyoming acquired a new position in shares of Medpace in the 2nd quarter worth approximately $88,000. GSA Capital Partners LLP bought a new position in shares of Medpace during the 2nd quarter worth approximately $208,000. MGO One Seven LLC boosted its stake in Medpace by 7.1% in the 2nd quarter. MGO One Seven LLC now owns 968 shares of the company’s stock valued at $513,000 after buying an additional 64 shares in the last quarter. Finally, Associated Banc Corp acquired a new stake in Medpace in the 2nd quarter valued at $204,000. Institutional investors and hedge funds own 77.98% of the company’s stock.
Medpace Stock Down 1.0% Shares of NASDAQ MEDP opened at $614.06 on Wednesday. Medpace Holdings, Inc. has a 12-month low of $373.00 and a 12-month high of $677.90. The firm’s 50-day simple moving average is $556.26 and its 200 day simple moving average is $492.77. The company has a market cap of $17.14 billion, a price-to-earnings ratio of 35.99, a price-to-earnings-growth ratio of 2.77 and a beta of 1.15.
Medpace (NASDAQ:MEDP – Get Free Report) last posted its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, beating the consensus estimate of $3.98 by $0.27. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The firm had revenue of $707.33 million during the quarter, compared to analysts’ expectations of $689.51 million. During the same quarter last year, the company posted $3.10 EPS. The company’s quarterly revenue was up 17.2% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, equities analysts expect that Medpace Holdings, Inc. will post 17.54 earnings per share for the current year. Insiders Place Their Bets In related news, CFO Kevin M. Brady sold 3,400 shares of the business’s stock in a transaction that occurred on Thursday, August 20th. The shares were sold at an average price of $625.24, for a total value of $2,125,816.00. Following the completion of the transaction, the chief financial officer owned 12,830 shares in the company, valued at $8,021,829.20. The trade was a 20.95% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Cornelius P. Mccarthy III sold 1,140 shares of the business’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $605.37, for a total transaction of $690,121.80. Following the completion of the transaction, the director owned 12,275 shares of the company’s stock, valued at $7,430,916.75. This trade represents a 8.50% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 141,639 shares of company stock valued at $83,824,038 over the last quarter. Company insiders own 20.50% of the company’s stock.
Wall Street Analyst Weigh In MEDP has been the subject of a number of analyst reports. Robert W. Baird lifted their price objective on Medpace from $547.00 to $624.00 and gave the company a “neutral” rating in a report on Friday, July 24th. Jefferies Financial Group lowered shares of Medpace from a “buy” rating to a “hold” rating and upped their target price for the stock from $490.00 to $515.00 in a report on Tuesday, July 7th. BMO Capital Markets increased their target price on shares of Medpace from $400.00 to $600.00 and gave the stock a “market perform” rating in a research report on Friday, July 24th. TD Cowen lifted their price target on shares of Medpace from $419.00 to $492.00 and gave the company a “hold” rating in a report on Friday, July 24th. Finally, Mizuho boosted their price target on shares of Medpace from $586.00 to $665.00 and gave the company an “outperform” rating in a research report on Friday, July 24th. Three investment analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company. According to MarketBeat.com, Medpace presently has an average rating of “Hold” and an average price target of $584.18.
Get Our Latest Report on Medpace
Key Headlines Impacting Medpace Here are the key news stories impacting Medpace this week:
Positive Sentiment: Medpace’s latest quarterly results were strong: earnings of $4.25 per share exceeded the $3.98 consensus estimate, while revenue rose 17.2% year over year to $707.33 million, ahead of expectations. Management’s fiscal 2026 EPS guidance is $17.25–$17.95. Institutional ownership is also high at approximately 78%, with several large investors adding positions. Neutral Sentiment: Reported short interest was listed at zero shares, with a zero-day days-to-cover ratio. Because the figures show no measurable short position, they provide little indication of near-term buying or selling pressure. Neutral Sentiment: Analyst sentiment remains mixed. The consensus rating is “Hold,” with an average price target of $584.18, below recent trading levels. BMO Capital Markets raised its target to $600 while maintaining a market-perform rating, and Weiss Ratings upgraded the stock to “Buy.” Negative Sentiment: Multiple company insiders recently sold shares. CEO August J. Troendle sold 13,995 shares for approximately $8.74 million on August 21 and another 1,983 shares for about $1.23 million on August 24. CFO Kevin Brady sold 3,400 shares worth roughly $2.13 million, reducing his ownership by 20.95%. Additional director sales were also reported. Although executives retain significant holdings, the concentration of selling can weigh on investor confidence. About Medpace (Free Report)
Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.
Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.
Read More Five stocks we like better than Medpace Pathward’s Credit Scare Tests Its Comeback Story Wiring the AI Boom: Rumble’s $13.7B Pivot StoneX: Too Far Too Fast? DICK’s Sporting Goods Faces Pain Now for a Bigger Prize Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report).
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.
August J. Troendle, President & CEO of Medpace Holdings, Inc. (MEDP -1.79%), sold 15,978 shares of common stock in a transaction valued at $10.0 million. SEC Form 4 filing
Transaction summaryMetricValueTransaction value$10.0 millionShares sold15,978Post-transaction shares (directly held)~545,217Post-transaction shares (indirectly held)~4.7 millionPost-transaction value$3.27 billionTransaction value based on SEC Form 4 weighted average sale price ($623.93); post-transaction value based on Aug. 24, 2026, market close ($620.03).
Key questionsWhat were the technical parameters of this transaction?
The disposition was executed as a series of sales at weighted average prices between $620.00 and $628.68 per share, following a limit order placed by the CEO during an open trading window.How does the CEO's remaining stake compare to the shares sold?
Following the $10.0 million sale, the CEO retains a combined direct and indirect position valued at $3.27 billion as of the Aug. 24, 2026, market close, representing 19% of the company's total market capitalization.What entity controls the indirect holdings?
The majority of the equity, totaling ~4.7 million shares, is held through Medpace Investors, LLC, in which Troendle serves as the sole manager and controlling unit holder, with exclusive voting and investment control.How has the stock performed leading up to this transaction?
The company's shares delivered a 34% one-year total return as of the Aug. 24, 2026 transaction date, with the firm recording TTM revenue of $2.8 billion and net income of $491.5 million.Company OverviewMetricValueShare Price (as of market close 2026-08-24)$620.03Market Capitalization$17.3 billionRevenue (TTM)$2.8 billionNet Income (TTM)$491.5 millionCompany SnapshotMedpace Holdings provides comprehensive contract research organization (CRO) services encompassing clinical development and research solutions across the entire pharmaceutical product lifecycle, from Phase I trials through Phase IV post-market surveillance.The company generates revenue through fee-for-service arrangements with pharmaceutical, biotechnology, and medical device manufacturers who outsource their clinical development and regulatory affairs functions to Medpace.Medpace serves a diversified client base of pharmaceutical, biotechnology, and medical device companies operating across North America, Europe, and Asia, with particular strength in supporting mid-sized and emerging biopharmaceutical firms.Medpace Holdings operates as a leading independent contract research organization with a global footprint, leveraging its 6,500-person workforce and established infrastructure to deliver integrated clinical development services. The company has demonstrated strong financial performance with TTM revenue of $2.8 billion and net income of $491.5 million, reflecting robust demand for outsourced clinical research capabilities. Medpace's competitive positioning is reinforced by its comprehensive service offerings, operational scale, and established relationships with pharmaceutical and biotechnology clients across multiple therapeutic areas.
What this transaction means for investorsWhile CEO Troendle's $10 million sale might look jarring, it shouldn't prove to be anything for investors to worry about. Troendle still holds 2.7 million shares worth $3.3 billion, so this latest selling activity is relatively minor by comparison. Holding nearly one-fifth of Medpace's outstanding shares, the CEO remains aligned with the company's long-term success.
As for Medpace, the stock continues to fire on all cylinders amid a biotech market rebound. MEDP stock has delivered annualized total returns of 36% since 2016 and has seen its shares rise 32% over the last year. The company grew sales and EPS by 17% and 37% in the last quarter, prompting its recent price run-up.
I'm happy to be a MEDP shareholder, but am not rushing to buy shares with the stock trading at 25 times free cash flow -- which is above its 10-year average of 20. That said, I'd be happy to buy on any dip or if the company's sales growth remains in the double-digits. Medpace's integrated full-service operating model positions it to benefit from AI over the long haul, as the booming technology could cut costs for the services it provides to its customers. Ultimately, interested investors shouldn't be afraid to buy MEDP stock at today's price, but they shouldn't expect any major share buyback plans from Troendle and Co. while shares trade at a slight premium.
Investors with an interest in Medical Services stocks have likely encountered both Concentra Group (CON - Free Report) and Medpace (MEDP - Free Report) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.
We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The Zacks Rank is a proven strategy that targets companies with positive earnings estimate revision trends, while our Style Scores work to grade companies based on specific traits.
Concentra Group and Medpace are both sporting a Zacks Rank of #2 (Buy) right now. The Zacks Rank favors stocks that have recently seen positive revisions to their earnings estimates, so investors should rest assured that both of these companies have improving earnings outlooks. However, value investors will care about much more than just this.
Value investors also tend to look at a number of traditional, tried-and-true figures to help them find stocks that they believe are undervalued at their current share price levels.
The Value category of the Style Scores system identifies undervalued companies by looking at a number of key metrics. These include the long-favored P/E ratio, P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that help us determine a company's fair value.
CON currently has a forward P/E ratio of 21.70, while MEDP has a forward P/E of 35.07. We also note that CON has a PEG ratio of 1.30. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. MEDP currently has a PEG ratio of 2.74.
Another notable valuation metric for CON is its P/B ratio of 9.18. Investors use the P/B ratio to look at a stock's market value versus its book value, which is defined as total assets minus total liabilities. By comparison, MEDP has a P/B of 39.5.
These are just a few of the metrics contributing to CON's Value grade of B and MEDP's Value grade of D.
Both CON and MEDP are impressive stocks with solid earnings outlooks, but based on these valuation figures, we feel that CON is the superior value option right now.
Information in Investor’s Business Daily is for informational and educational purposes only and should not be construed as an offer, recommendation, solicitation, or rating to buy or sell securities. The information has been obtained from sources we believe to be reliable, but we make no guarantee as to its accuracy, timeliness, or suitability, including with respect to information that appears in closed captioning. Historical investment performances are no indication or guarantee of future success or performance. Authors/presenters may own the stocks they discuss. We make no representations or warranties regarding the advisability of investing in any particular securities or utilizing any specific investment strategies. Information is subject to change without notice. For information on use of our services, please see our Terms of Use.
*Real-time prices by Nasdaq Last Sale. Real-time quote and/or trade prices are not sourced from all markets. Ownership data provided by LSEG and Estimate data provided by FactSet.
IBD, IBD Digital, IBD Live, IBD Weekly, Investor's Business Daily, Leaderboard, MarketDiem, MarketSurge and other marks are trademarks owned by Investor's Business Daily, LLC.
American Capital Management Inc. bought a new stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 210,217 shares of the company’s stock, valued at approximately $111,329,000. Medpace makes up about 5.0% of American Capital Management Inc.’s investment portfolio, making the stock its 3rd largest holding. American Capital Management Inc. owned approximately 0.75% of Medpace as of its most recent SEC filing.
A number of other institutional investors also recently bought and sold shares of the stock. BlackRock Inc. bought a new position in Medpace in the second quarter worth $1,323,047,000. AQR Capital Management LLC lifted its position in Medpace by 31.6% during the 4th quarter. AQR Capital Management LLC now owns 1,349,703 shares of the company’s stock valued at $758,061,000 after acquiring an additional 324,293 shares during the period. Wasatch Advisors LP lifted its position in Medpace by 14.0% during the 2nd quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock valued at $296,853,000 after acquiring an additional 116,354 shares during the period. Geode Capital Management LLC boosted its stake in Medpace by 3.8% during the fourth quarter. Geode Capital Management LLC now owns 667,298 shares of the company’s stock worth $374,836,000 after acquiring an additional 24,625 shares in the last quarter. Finally, Invesco Ltd. boosted its stake in Medpace by 18.9% during the third quarter. Invesco Ltd. now owns 537,407 shares of the company’s stock worth $276,313,000 after acquiring an additional 85,517 shares in the last quarter. 77.98% of the stock is owned by institutional investors.
Medpace Trading Up 0.8% Medpace stock opened at $619.05 on Thursday. Medpace Holdings, Inc. has a 12 month low of $373.00 and a 12 month high of $677.90. The stock has a fifty day simple moving average of $559.49 and a two-hundred day simple moving average of $493.31. The firm has a market cap of $17.28 billion, a price-to-earnings ratio of 36.29, a PEG ratio of 2.74 and a beta of 1.15.
Medpace (NASDAQ:MEDP – Get Free Report) last issued its earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, topping analysts’ consensus estimates of $3.98 by $0.27. The business had revenue of $707.33 million during the quarter, compared to analyst estimates of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.Medpace’s revenue was up 17.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, equities research analysts forecast that Medpace Holdings, Inc. will post 17.54 EPS for the current fiscal year. Insider Activity In related news, Director Fred B. Davenport, Jr. sold 7,283 shares of Medpace stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $606.15, for a total transaction of $4,414,590.45. Following the transaction, the director owned 3,798 shares in the company, valued at approximately $2,302,157.70. The trade was a 65.73% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO August J. Troendle sold 27,174 shares of the stock in a transaction on Thursday, August 20th. The stock was sold at an average price of $618.79, for a total value of $16,814,999.46. Following the completion of the sale, the chief executive officer owned 561,195 shares of the company’s stock, valued at $347,261,854.05. The trade was a 4.62% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 125,290 shares of company stock valued at $76,466,988. Company insiders own 20.50% of the company’s stock.
Medpace News Roundup Here are the key news stories impacting Medpace this week:
Positive Sentiment: Medpace remains near a potential technical buy point of $628.92 after its July advance. The stock is trading well above its 50-day and 200-day moving averages, indicating sustained momentum. Medpace Stock Hovers Near Entry, Offers Second Chance After July Spike Positive Sentiment: The company’s latest quarterly results exceeded expectations: adjusted earnings were $4.25 per share versus the $3.98 consensus estimate, while revenue rose 17.2% year over year to $707.33 million, surpassing forecasts. Fiscal 2026 EPS guidance remains $17.25 to $17.95. Positive Sentiment: Institutional investors and hedge funds own approximately 78% of Medpace, and several investment firms have recently increased their positions. Some analysts have also raised price targets, including RBC’s $692 target and Mizuho’s $665 target. Neutral Sentiment: Value-focused investors are comparing Medpace with Concentra Group, but the available report does not establish a clear valuation advantage for MEDP. The stock trades at roughly 36 times earnings, with a PEG ratio above 2.7, suggesting investors are already paying a premium for growth. CON vs. MEDP: Which Stock Should Value Investors Buy Now? Neutral Sentiment: Reported short interest was zero shares, producing a zero-day days-to-cover ratio. This provides no meaningful evidence of short-covering demand or downside pressure. Negative Sentiment: Several executives have recently sold shares near $620–$625. CEO August Troendle sold 15,978 shares in two transactions worth approximately $9.97 million, while CFO Kevin Brady sold 3,400 shares valued at about $2.13 million. Although both executives retain shares, the concentration of insider selling could weigh on sentiment. Medpace CEO August Troendle Sells 1,983 Shares Negative Sentiment: Analyst opinion remains cautious overall: the consensus rating is “Hold,” and the average price target of $584.18 is below recent trading levels. This may make additional upside more difficult without another earnings or guidance catalyst. Wall Street Analysts Forecast Growth A number of equities analysts have weighed in on MEDP shares. Leerink Partners set a $620.00 target price on shares of Medpace in a research note on Thursday, July 23rd. Mizuho boosted their target price on Medpace from $586.00 to $665.00 and gave the stock an “outperform” rating in a report on Friday, July 24th. Robert W. Baird raised their price target on Medpace from $547.00 to $624.00 and gave the company a “neutral” rating in a report on Friday, July 24th. Jefferies Financial Group lowered Medpace from a “buy” rating to a “hold” rating and lifted their price target for the stock from $490.00 to $515.00 in a research report on Tuesday, July 7th. Finally, Weiss Ratings upgraded shares of Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, August 12th. Three equities research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. According to data from MarketBeat.com, Medpace has a consensus rating of “Hold” and an average target price of $584.18.
Read Our Latest Report on MEDP
Medpace Profile (Free Report)
Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.
Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.
Featured Articles Five stocks we like better than Medpace Williams-Sonoma’s Quarter Gave Bulls More Than Just a Beat-and-Raise Alcoa’s Gallium Project Opens a New Door Beyond Aluminum Oura’s $16 Billion IPO Could Put a New Price on Wearable Tech Can Tesla’s Flying Roadster Distract From Its Real Risks?
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.
B. Metzler seel. Sohn & Co. AG purchased a new stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 8,944 shares of the company’s stock, valued at approximately $4,737,000.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. NewEdge Advisors LLC boosted its position in Medpace by 22.1% during the 1st quarter. NewEdge Advisors LLC now owns 1,048 shares of the company’s stock valued at $319,000 after acquiring an additional 190 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of Medpace by 3.8% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 81,817 shares of the company’s stock worth $24,929,000 after acquiring an additional 3,010 shares in the last quarter. Geneos Wealth Management Inc. lifted its stake in shares of Medpace by 64.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after purchasing an additional 37 shares during the last quarter. Sivia Capital Partners LLC bought a new stake in Medpace during the second quarter valued at about $296,000. Finally, M&T Bank Corp boosted its position in Medpace by 3.4% during the second quarter. M&T Bank Corp now owns 939 shares of the company’s stock valued at $295,000 after purchasing an additional 31 shares in the last quarter. 77.98% of the stock is currently owned by institutional investors.
Medpace Stock Up 1.3% Shares of NASDAQ MEDP opened at $620.75 on Friday. Medpace Holdings, Inc. has a 52 week low of $373.00 and a 52 week high of $677.90. The business’s 50 day moving average price is $550.16 and its 200 day moving average price is $492.71. The firm has a market cap of $17.33 billion, a P/E ratio of 36.39, a P/E/G ratio of 2.73 and a beta of 1.15.
Medpace (NASDAQ:MEDP – Get Free Report) last posted its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.98 by $0.27. The company had revenue of $707.33 million during the quarter, compared to analyst estimates of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. Medpace’s revenue for the quarter was up 17.2% compared to the same quarter last year. During the same period last year, the firm posted $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, research analysts expect that Medpace Holdings, Inc. will post 17.54 earnings per share for the current year. Insiders Place Their Bets In other news, Director Brian T. Carley sold 5,000 shares of the stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $608.63, for a total transaction of $3,043,150.00. Following the sale, the director directly owned 27,825 shares of the company’s stock, valued at $16,935,129.75. This represents a 15.23% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Susan E. Burwig sold 7,500 shares of the firm’s stock in a transaction dated Tuesday, July 28th. The shares were sold at an average price of $600.00, for a total value of $4,500,000.00. Following the sale, the vice president owned 62,984 shares in the company, valued at $37,790,400. This trade represents a 10.64% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 122,261 shares of company stock worth $71,729,129. Corporate insiders own 20.50% of the company’s stock.
Analyst Upgrades and Downgrades A number of brokerages have recently issued reports on MEDP. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and issued a $535.00 price objective on shares of Medpace in a research report on Thursday, July 23rd. Royal Bank Of Canada upped their price target on Medpace from $484.00 to $692.00 and gave the stock an “outperform” rating in a research report on Friday, July 24th. Leerink Partners set a $620.00 price objective on Medpace in a report on Thursday, July 23rd. Robert W. Baird raised their price objective on Medpace from $547.00 to $624.00 and gave the stock a “neutral” rating in a research report on Friday, July 24th. Finally, Jefferies Financial Group cut Medpace from a “buy” rating to a “hold” rating and increased their price target for the company from $490.00 to $515.00 in a research note on Tuesday, July 7th. Three investment analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company’s stock. According to data from MarketBeat, Medpace currently has a consensus rating of “Hold” and a consensus target price of $584.18.
View Our Latest Analysis on Medpace
Medpace Company Profile (Free Report)
Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.
Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.
Recommended Stories Five stocks we like better than Medpace Blueprint for a Boom: SEC Clears the Crypto Runway Ross Stores Just Flipped the Off-Price Retail Story After TJX’s Marmaxx Miss Advance Auto Parts Plunged, But Its Turnaround Is Still Working Is Palo Alto Networks Priced for Perfection Again as AI Security Demand Accelerates? Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report).
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.
Allworth Financial LP acquired a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 3,894 shares of the company’s stock, valued at approximately $2,062,000.
A number of other hedge funds also recently made changes to their positions in the business. BlackRock Inc. bought a new position in Medpace during the second quarter worth $1,323,047,000. AQR Capital Management LLC raised its position in shares of Medpace by 65.1% in the third quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company’s stock valued at $518,170,000 after purchasing an additional 404,226 shares during the period. Madison Asset Management LLC bought a new position in shares of Medpace in the second quarter valued at about $128,956,000. Arrowstreet Capital Limited Partnership lifted its stake in shares of Medpace by 205.8% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 314,150 shares of the company’s stock worth $161,523,000 after buying an additional 211,411 shares during the last quarter. Finally, Franklin Resources Inc. lifted its stake in shares of Medpace by 158.6% during the 4th quarter. Franklin Resources Inc. now owns 299,472 shares of the company’s stock worth $168,198,000 after buying an additional 183,645 shares during the last quarter. 77.98% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In A number of research analysts recently commented on the stock. TD Cowen upped their price target on shares of Medpace from $419.00 to $492.00 and gave the company a “hold” rating in a research note on Friday, July 24th. Royal Bank Of Canada upped their target price on Medpace from $484.00 to $692.00 and gave the company an “outperform” rating in a research report on Friday, July 24th. Leerink Partners set a $620.00 target price on Medpace in a research note on Thursday, July 23rd. Wall Street Zen cut Medpace from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Finally, Mizuho lifted their price target on Medpace from $586.00 to $665.00 and gave the stock an “outperform” rating in a report on Friday, July 24th. Three equities research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $584.18.
Get Our Latest Stock Report on MEDP Insider Buying and Selling at Medpace In related news, Director Fred B. Davenport, Jr. sold 7,283 shares of Medpace stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $606.15, for a total transaction of $4,414,590.45. Following the sale, the director directly owned 3,798 shares in the company, valued at $2,302,157.70. This trade represents a 65.73% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Brian T. Carley sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $608.63, for a total transaction of $3,043,150.00. Following the sale, the director directly owned 27,825 shares in the company, valued at $16,935,129.75. The trade was a 15.23% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 122,261 shares of company stock worth $71,729,129 over the last quarter. Insiders own 20.50% of the company’s stock.
Medpace Stock Performance Shares of NASDAQ:MEDP opened at $620.75 on Friday. Medpace Holdings, Inc. has a 52-week low of $373.00 and a 52-week high of $677.90. The company has a market capitalization of $17.33 billion, a PE ratio of 36.39, a price-to-earnings-growth ratio of 2.73 and a beta of 1.15. The company has a fifty day moving average of $550.16 and a 200-day moving average of $492.71.
Medpace (NASDAQ:MEDP – Get Free Report) last released its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, beating the consensus estimate of $3.98 by $0.27. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The company had revenue of $707.33 million for the quarter, compared to the consensus estimate of $689.51 million. During the same quarter last year, the business posted $3.10 EPS. Medpace’s revenue for the quarter was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, equities analysts forecast that Medpace Holdings, Inc. will post 17.54 EPS for the current fiscal year.
Medpace Company Profile (Free Report)
Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.
Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.
Recommended Stories Five stocks we like better than Medpace Blueprint for a Boom: SEC Clears the Crypto Runway Ross Stores Just Flipped the Off-Price Retail Story After TJX’s Marmaxx Miss Advance Auto Parts Plunged, But Its Turnaround Is Still Working Is Palo Alto Networks Priced for Perfection Again as AI Security Demand Accelerates?
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.
It has been about a month since the last earnings report for Medpace (MEDP - Free Report) . Shares have added about 1.1% in that time frame, underperforming the S&P 500.
But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is Medpace due for a pullback? Well, first let's take a quick look at the most recent earnings report in order to get a better handle on the recent drivers for Medpace Holdings, Inc. before we dive into how investors and analysts have reacted as of late.
MEDP Q2 Earnings and Revenues Surpass EstimatesMedpace Holdings, Inc.reported second-quarter 2026 earnings of $4.25 per share, up 37.1% year over year. The figure beat the Zacks Consensus Estimate by 4.17%.
Revenues rose 17.2% to $707.33 million and surpassed the consensus mark by 1.12%. On a constant-currency basis, growth was also 17.2%, indicating that foreign exchange had little effect on the reported expansion.
Medpace Posts Record Quarterly Awards
Net new business awards jumped 28.2% to $795.7 million, driving a net book-to-bill ratio of 1.13. Management attributed the record net bookings performance partly to a meaningful decline in cancellations from elevated first-quarter levels.
Backlog as of June 30, 2026 rose 4.9% year over year to $3.01 billion. Medpace expects about $1.96 billion of backlog to convert into revenues over the next 12 months. The quarterly backlog conversion rate increased to 24.1% from 21.2% a year ago.
MEDP Sees Oncology Regain Momentum
Management said oncology accounted for more than half of second-quarter bookings and initial award notifications. This marked a shift from the recent period when cardiometabolic programs were a larger contributor to business growth.
Medpace expects oncology to move back toward a more historically typical share of its portfolio over the next year. Cardiometabolic award notifications have moderated, while oncology opportunities have strengthened. The company also reported meaningfully higher request-for-proposal activity both sequentially and year over year.
Medpace Highlights Cash Position and Buybacks
Cash and cash equivalents totaled $502.7 million at the second quarter-end compared with $652.7 million as of March 31, 2026.
Net days sales outstanding remained favorable at negative 59.6 days.
Cumulative cash flow from operating activities came in at $162 million compared with $274.4 million a year ago.
MEDP repurchased approximately 706,000 shares for $294.7 million during the second quarter. The company had $527 million remaining under its authorized share repurchase program at quarter-end.
MEDP Raises Its 2026 Outlook
Medpace now expects 2026 revenues of $2.805-$2.885 billion, implying growth of 10.9%-14% over 2025 levels. The Zacks Consensus Estimate for revenues stands at $2.84 billion.
EBITDA is projected between $618 million and $642 million, suggesting growth of 10.8%-15.1%.
GAAP net income is forecast at $494-$514 million, while earnings are expected between $17.25 and $17.95 per share. The Zacks Consensus Estimate expects earnings to be $17.51 per share. The guidance assumes a 19%-19.5% tax rate, $21.1 million of interest income and no additional share repurchases after June 30.
How Have Estimates Been Moving Since Then?In the past month, investors have witnessed a upward trend in fresh estimates.
The consensus estimate has shifted 5.61% due to these changes.
VGM ScoresCurrently, Medpace has a strong Growth Score of A, though it is lagging a lot on the Momentum Score front with an F. Charting a somewhat similar path, the stock has a grade of D on the value side, putting it in the bottom 40% for value investors.
Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.
OutlookEstimates have been trending upward for the stock, and the magnitude of this revision looks promising. It comes with little surprise Medpace has a Zacks Rank #2 (Buy). We expect an above average return from the stock in the next few months.
Performance of an Industry PlayerMedpace belongs to the Zacks Medical Services industry. Another stock from the same industry, Elevance Health (ELV - Free Report) , has gained 4.5% over the past month. More than a month has passed since the company reported results for the quarter ended June 2026.
Elevance Health reported revenues of $49.83 billion in the last reported quarter, representing a year-over-year change of +0.8%. EPS of $7.45 for the same period compares with $8.84 a year ago.
Elevance Health is expected to post earnings of $4.82 per share for the current quarter, representing a year-over-year change of -20.1%. Over the last 30 days, the Zacks Consensus Estimate has changed -1.5%.
Elevance Health has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of B.
Abacus FCF Advisors LLC acquired a new stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 12,529 shares of the company’s stock, valued at approximately $6,635,000.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Johnson Financial Group Inc. purchased a new position in Medpace in the second quarter worth $27,000. Elyxium Wealth LLC acquired a new position in Medpace during the 4th quarter valued at about $30,000. Allied Private Wealth LLC acquired a new position in Medpace during the 2nd quarter valued at about $31,000. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in Medpace in the second quarter valued at about $34,000. Finally, Basecamp Wealth Advisors LLC raised its stake in Medpace by 187.5% in the first quarter. Basecamp Wealth Advisors LLC now owns 69 shares of the company’s stock valued at $33,000 after buying an additional 45 shares during the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.
Medpace Price Performance NASDAQ MEDP opened at $608.27 on Thursday. The company has a market capitalization of $16.98 billion, a PE ratio of 35.65, a P/E/G ratio of 2.63 and a beta of 1.15. The company has a fifty day moving average of $544.34 and a 200 day moving average of $491.59. Medpace Holdings, Inc. has a 1 year low of $373.00 and a 1 year high of $677.90.
Medpace (NASDAQ:MEDP – Get Free Report) last announced its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, topping the consensus estimate of $3.98 by $0.27. The company had revenue of $707.33 million for the quarter, compared to the consensus estimate of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The firm’s revenue for the quarter was up 17.2% compared to the same quarter last year. During the same period last year, the firm earned $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Research analysts expect that Medpace Holdings, Inc. will post 17.54 earnings per share for the current year. Insider Buying and Selling In related news, Director Cornelius P. Mccarthy III sold 1,140 shares of the firm’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $605.37, for a total transaction of $690,121.80. Following the sale, the director owned 12,275 shares in the company, valued at approximately $7,430,916.75. This trade represents a 8.50% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO August J. Troendle sold 17,610 shares of the firm’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $605.11, for a total transaction of $10,655,987.10. Following the sale, the chief executive officer owned 615,802 shares in the company, valued at approximately $372,627,948.22. This represents a 2.78% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 67,195 shares of company stock valued at $37,989,998. Insiders own 20.50% of the company’s stock.
Analyst Ratings Changes MEDP has been the subject of several research analyst reports. Leerink Partners set a $620.00 price objective on shares of Medpace in a research report on Thursday, July 23rd. Weiss Ratings raised shares of Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, August 12th. Royal Bank Of Canada upped their price target on shares of Medpace from $484.00 to $692.00 and gave the company an “outperform” rating in a research note on Friday, July 24th. BMO Capital Markets raised their price target on shares of Medpace from $400.00 to $600.00 and gave the stock a “market perform” rating in a report on Friday, July 24th. Finally, Mizuho lifted their price objective on shares of Medpace from $586.00 to $665.00 and gave the stock an “outperform” rating in a research note on Friday, July 24th. Three investment analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $584.18.
Get Our Latest Report on Medpace
Medpace Profile (Free Report)
Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.
Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.
Recommended Stories Five stocks we like better than Medpace Bloom Energy’s AI Surge Meets a Valuation Reality Check Target Is Winning Shoppers Back—Can the Rally Reach $180? IonQ’s Space Contract Points to a New Frontier for Quantum Investors Is Apple’s AI Strategy Smarter Than Skeptics Think?
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.
Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. But finding a growth stock that can live up to its true potential can be a tough task.
In addition to volatility, these stocks carry above-average risk by their very nature. Also, one could end up losing from a stock whose growth story is actually over or nearing its end.
However, the task of finding cutting-edge growth stocks is made easy with the help of the Zacks Growth Style Score (part of the Zacks Style Scores system), which looks beyond the traditional growth attributes to analyze a company's real growth prospects.
Our proprietary system currently recommends Medpace (MEDP - Free Report) as one such stock. This company not only has a favorable Growth Score, but also carries a top Zacks Rank.
Research shows that stocks carrying the best growth features consistently beat the market. And returns are even better for stocks that possess the combination of a Growth Score of A or B and a Zacks Rank #1 (Strong Buy) or 2 (Buy).
While there are numerous reasons why the stock of this provider of outsourced clinical development services is a great growth pick right now, we have highlighted three of the most important factors below:
Earnings GrowthEarnings growth is arguably the most important factor, as stocks exhibiting exceptionally surging profit levels tend to attract the attention of most investors. For growth investors, double-digit earnings growth is highly preferable, as it is often perceived as an indication of strong prospects (and stock price gains) for the company under consideration.
While the historical EPS growth rate for Medpace is 31.2%, investors should actually focus on the projected growth. The company's EPS is expected to grow 14.6% this year, crushing the industry average, which calls for EPS growth of 13.7%.
Cash Flow GrowthCash is the lifeblood of any business, but higher-than-average cash flow growth is more beneficial and important for growth-oriented companies than for mature companies. That's because, high cash accumulation enables these companies to undertake new projects without raising expensive outside funds.
Right now, year-over-year cash flow growth for Medpace is 10.5%, which is higher than many of its peers. In fact, the rate compares to the industry average of 0.5%.
While investors should actually consider the current cash flow growth, it's worth taking a look at the historical rate too for putting the current reading into proper perspective. The company's annualized cash flow growth rate has been 23% over the past 3-5 years versus the industry average of 10.8%.
Promising Earnings Estimate RevisionsBeyond the metrics outlined above, investors should consider the trend in earnings estimate revisions. A positive trend is a plus here. Empirical research shows that there is a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
The current-year earnings estimates for Medpace have been revising upward. The Zacks Consensus Estimate for the current year has surged 2.9% over the past month.
Bottom LineMedpace has not only earned a Growth Score of A based on a number of factors, including the ones discussed above, but it also carries a Zacks Rank #2 because of the positive earnings estimate revisions.
You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
This combination positions Medpace well for outperformance, so growth investors may want to bet on it.
Medpace Holdings, Inc. (NASDAQ:MEDP – Get Free Report) CEO August Troendle sold 11,366 shares of the business’s stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $601.53, for a total value of $6,836,989.98. Following the completion of the sale, the chief executive officer owned 604,436 shares in the company, valued at $363,586,387.08. This represents a 1.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Medpace Price Performance NASDAQ MEDP opened at $578.50 on Monday. The stock has a market capitalization of $16.15 billion, a PE ratio of 33.91, a P/E/G ratio of 2.58 and a beta of 1.15. The business has a 50 day simple moving average of $536.23 and a two-hundred day simple moving average of $491.58. Medpace Holdings, Inc. has a 1-year low of $373.00 and a 1-year high of $677.90.
Medpace (NASDAQ:MEDP – Get Free Report) last issued its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.98 by $0.27. The business had revenue of $707.33 million for the quarter, compared to analysts’ expectations of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The company’s revenue for the quarter was up 17.2% on a year-over-year basis. During the same period in the prior year, the firm earned $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, analysts anticipate that Medpace Holdings, Inc. will post 17.54 EPS for the current fiscal year.
Institutional Trading of Medpace Hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Inc. bought a new stake in shares of Medpace in the 2nd quarter worth about $1,323,047,000. AQR Capital Management LLC grew its holdings in Medpace by 65.1% during the 3rd quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company’s stock valued at $518,170,000 after purchasing an additional 404,226 shares during the last quarter. Madison Asset Management LLC bought a new position in Medpace during the 2nd quarter valued at about $128,956,000. Arrowstreet Capital Limited Partnership raised its position in Medpace by 205.8% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 314,150 shares of the company’s stock worth $161,523,000 after purchasing an additional 211,411 shares during the period. Finally, American Capital Management Inc. purchased a new stake in Medpace in the 2nd quarter worth about $111,329,000. Hedge funds and other institutional investors own 77.98% of the company’s stock. Wall Street Analyst Weigh In MEDP has been the subject of several research reports. Royal Bank Of Canada increased their price objective on shares of Medpace from $484.00 to $692.00 and gave the company an “outperform” rating in a research report on Friday, July 24th. Robert W. Baird boosted their target price on shares of Medpace from $547.00 to $624.00 and gave the stock a “neutral” rating in a report on Friday, July 24th. BMO Capital Markets upped their target price on shares of Medpace from $400.00 to $600.00 and gave the company a “market perform” rating in a research report on Friday, July 24th. Leerink Partners set a $620.00 target price on shares of Medpace in a research report on Thursday, July 23rd. Finally, Wall Street Zen downgraded shares of Medpace from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Three investment analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Medpace currently has an average rating of “Hold” and a consensus price target of $584.18.
Check Out Our Latest Analysis on MEDP
About Medpace (Get Free Report)
Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.
Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.
Featured Articles Five stocks we like better than Medpace The Metals Company’s Big Bet Now Comes Down to a License OneSpaWorld Keeps Turning Cruise Demand Into Record Earnings Meta and Tesla Are Rebounding From Oversold Levels—Now What? AMG’s Alternatives Boom Powers Record Growth
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.
Investors interested in stocks from the Medical Services sector have probably already heard of Concentra Group (CON) and Medpace (MEDP). But which of these two stocks presents investors with the better value opportunity right now?
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.
Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.
Zacks Premium also includes the Zacks Style Scores.
What are the Zacks Style Scores? The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest chances of beating the market over the next 30 days.
Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value ScoreValue investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and many other multiples, the Value Style Score identifies the most attractive and most discounted stocks.
Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.
Momentum ScoreMomentum investors, who live by the saying "the trend is your friend," are most interested in taking advantage of upward or downward trends in a stock's price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks.
VGM ScoreIf you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.
How Style Scores Work with the Zacks Rank The Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make building a winning portfolio easier.
Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +23.94% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.
That's where the Style Scores come in.
You want to make sure you're buying stocks with the highest likelihood of success, and to do that, you'll need to pick stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you like a stock that only has a #3 (Hold) rank, it should also have Scores of A or B to guarantee as much upside potential as possible.
Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.
For instance, a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one that boasts Scores of A and B, still has a downward-trending earnings forecast, and a much greater likelihood its share price will decline as well.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Medpace (MEDP - Free Report) Medpace Holdings, Inc. is a global clinical contract research organization (CRO) delivering full-service Phase I-IV drug and device development support, including protocol and project management, regulatory affairs, clinical monitoring, data management/analysis, pharmacovigilance, submission support, and specialized services such as bioanalytical labs and medical imaging. The company is headquartered in Cincinnati, OH, and employed approximately 6,500 people across 46 countries as of June 30, 2026.
MEDP is a #2 (Buy) on the Zacks Rank, with a VGM Score of B.
Additionally, the company could be a top pick for growth investors. MEDP has a Growth Style Score of A, forecasting year-over-year earnings growth of 14.6% for the current fiscal year.
Five analysts revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.47 to $17.51 per share. MEDP also boasts an average earnings surprise of +10.2%.
With a solid Zacks Rank and top-tier Growth and VGM Style Scores, MEDP should be on investors' short list.
, /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Medpace Holdings, Inc. (NASDAQ: MEDP) breached their fiduciary duties to shareholders.
According to a federal securities lawsuit, Medpace Holdings misrepresented or failed to disclose material information concerning the Company's backlog cancellation rates, business conditions, and ability to maintain its projected 1.15 book-to-bill ratio. As a result, Medpace allegedly provided investors with overly optimistic growth expectations, causing investors to purchase the Company's common stock at artificially inflated prices.
If you currently own MEDP and purchased prior to April 22, 2025 please contact Sophia Anne Silayan by email at [email protected] or call (833) 672-0814. Kuehn Law pays all case costs and does not charge its investor clients. Shareholders should contact the firm immediately as there may be limited time to enforce your rights.
Why Your Participation Matters:
As a shareholder your voice matters, and by getting involved, you contribute to the integrity and fairness of the financial markets. Your investment. Your voice. Your future.™
Medpace Holdings, Inc. (MEDP - Free Report) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, MEDP's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross."
Considered an important signifier for a bullish breakout, a golden cross is a technical chart pattern that's formed when a stock's short-term moving average breaks above a longer-term moving average; the most common crossover involves the 50-day and the 200-day, since bigger time periods tend to form stronger breakouts.
There are three stages to a golden cross. First, there must be a downtrend in a stock's price that eventually bottoms out. Then, the stock's shorter moving average crosses over its longer moving average, triggering a positive trend reversal. The third stage is when a stock continues the upward momentum to higher prices.
A golden cross contrasts with a death cross, another widely-followed chart pattern that suggests bearish momentum could be on the horizon.
Shares of MEDP have been moving higher over the past four weeks, up 9.3%. Plus, the company is currently a #2 (Buy) on the Zacks Rank, suggesting that MEDP could be poised for a breakout.
The bullish case only gets stronger once investors take into account MEDP's positive earnings outlook for the current quarter. There have been 5 upward revisions compared to none lower over the past 60 days, and the Zacks Consensus Estimate has moved up as well.
Given this move in earnings estimates and the positive technical factor, investors may want to keep their eye on MEDP for more gains in the near future.
Key Takeaways Medpace posted record second-quarter net new business awards and ended with a $3.01 billion backlog.MEDP expects much of its recent pipeline to support 2027 as studies move into active work.MEDP trades well above industry valuation levels, leaving less room for execution missteps. Medpace Holdings, Inc. (MEDP - Free Report) combines double-digit earnings growth, resilient profitability and improving bookings with a valuation far above industry and market levels.
The central question is whether its operating quality and 2027 pipeline justify that premium or whether uneven conversion and cancellation risk favor a more selective entry point.
MEDP’s Growth Profile Remains CompellingThe Zacks Consensus Estimate calls for 2026 sales growth of 12.4% and earnings growth of 14.6%, following roughly 20% revenue growth in 2025. That outlook points to continued expansion even as the pace normalizes from the prior year.
Image Source: Zacks Investment Research
Medpace’s full-service model and centralized operating structure support consistent execution across clinical programs. Its disciplined cost base has also helped earnings grow without sacrificing profitability. Larger peers such as IQVIA Holdings Inc. (IQV - Free Report) and ICON plc (ICLR - Free Report) show how scale and end-to-end clinical capabilities remain central competitive factors in the contract research market.
Medpace’s Pipeline Offers a 2027 CatalystSecond-quarter net new business awards reached a record $795.7 million, up 28.2% year over year, while request-for-proposal activity increased sequentially and year over year. Ending backlog was $3.01 billion, with about $1.96 billion expected to convert over the next 12 months.
The benefit will not arrive all at once. Many recently awarded programs remain in pre-backlog, and some studies need time to move from notification to active work. That makes the current pipeline more relevant to 2027 than to an immediate revenue acceleration.
MEDP’s Margins and Cash Add SupportSecond-quarter EBITDA rose 17.6% to $153.4 million, and the EBITDA margin held at 21.7% versus 21.6% a year earlier. Free cash flow reached $138.1 million after capital expenditures.
Medpace ended June with $502.7 million in cash, no debt and $527 million remaining under its repurchase authorization. That liquidity gives the company room to fund hiring, technology spending and campus investment while retaining flexibility for additional capital returns.
Medpace’s Premium Valuation Limits FlexibilityMEDP trades at 31.8X forward 12-month earnings, compared with 16.1X for the Zacks sub-industry and 20.6X for both the Zacks Medical sector and the S&P 500. Its price-to-sales ratio of 5.8 and EV-to-EBITDA multiple of 27.8 also stand well above the industry’s 1.4 and 2.2, respectively.
Image Source: Zacks Investment Research
Those premiums leave little room for execution slippage. Continued earnings delivery, backlog conversion and stable margins are needed to support the current multiple, while any bookings or guidance disappointment could pressure the shares.
MEDP Still Faces Uneven VisibilityThe top five customers generated 31% of trailing 12-month revenues. Cardiometabolic award activity has moderated, while oncology represented more than half of recent bookings and award notifications.
That mix shift could lengthen conversion timing, and cancellations remain difficult to predict. Reimbursed out-of-pocket expenses were about 43% of second-quarter revenues, making reported growth and margin trends harder to interpret when pass-through activity changes.
MEDP’s Quality Signals Favor SelectivityMEDP’s growth, margins and balance sheet support a favorable operating view, but the premium valuation and uneven booking visibility argue against an unqualified stance.
The stock carries a Zacks Rank #2 (Buy) and a Growth Score of A, indicating positive earnings-estimate momentum and attractive growth characteristics. Its Value Score of D and Momentum Score of C are less supportive, while the VGM Score of B offers a balanced overall profile. Together, these signals favor selectivity rather than chasing the stock at any price.
You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Key Takeaways Medpace posted record Q2 net new business awards of $795.7 million, lifting book-to-bill to 1.13.MEDP's backlog reached $3.01 billion, with about $1.96 billion expected to convert within 12 months.MEDP's record bookings were helped by lower cancellations, which remain difficult to forecast. Medpace Holdings, Inc. (MEDP - Free Report) regained commercial momentum in the second quarter of 2026 as record awards and a higher book-to-bill ratio reversed the weaker first-quarter trend.
The central issue is timing. Better demand can strengthen backlog and support future growth, but study starts, pre-backlog work and unpredictable cancellations may delay the larger revenue benefit until 2027.
MEDP Delivers Record Quarterly AwardsNet new business awards increased 28.2% year over year to $795.7 million, the highest quarterly level reported by Medpace. The result lifted net book-to-bill to 1.13, meaning awards exceeded second-quarter revenues.
That was a clear improvement from the first quarter's 0.88 ratio. The rebound indicates that commercial activity recovered enough to replace revenue consumed during the quarter and begin rebuilding forward coverage.
Medpace’s Demand Indicators BroadenRequest-for-proposal activity increased both sequentially and year over year, while win rates recovered after management's improvement initiatives. Client funding activity also remained constructive, supporting a broader opportunity set.
Management expects gross bookings to ramp during the second half. That outlook is relevant across the contract research market, where ICON plc (ICLR - Free Report) provides integrated clinical development services and IQVIA Holdings Inc. (IQV - Free Report) combines clinical research services with healthcare data and analytics. For MEDP, stronger gross awards will matter most if cancellations stay within a reasonable range.
MEDP’s Oncology Mix Reshapes the PipelineOncology represented more than half of second-quarter bookings and initial award notifications. At the same time, new cardiometabolic award activity moderated as several large metabolic programs moved closer to maturity.
The shift reduces reliance on the therapeutic area that recently drove growth and moves the pipeline toward Medpace's historical mix. Yet oncology programs can carry different award, study-start and conversion patterns, leaving the timing of revenue recognition less predictable.
Medpace’s Backlog Supports Revenue ContinuityEnding backlog increased 4.9% year over year to $3.01 billion. Medpace expects approximately $1.96 billion of that backlog to convert into revenues over the next 12 months, providing a meaningful base of contracted work.
The near-term conversion estimate does not capture the full potential of the second-quarter awards. Some programs remain in pre-backlog, while others need additional time before study activity begins. Those lags could push much of the incremental contribution into 2027.
Here's where the consensus estimates for the company's 2026 and 2027 sales currently stand.
Image Source: Zacks Investment Research
MEDP’s Cancellation Risk Clouds the RecoveryLower cancellations accounted for more than half of the sequential improvement in net bookings. That makes the quarterly record less straightforward than the headline figure suggests because part of the rebound came from fewer lost awards rather than gross-booking growth alone.
Management said cancellations cannot be forecast reliably and may arise without warning. A renewed spike could weaken net bookings, slow backlog expansion and delay the expected benefit from the stronger commercial pipeline.
MEDP’s Growth Signals Support Cautious OptimismThe second-quarter recovery improves MEDP's path toward stronger 2027 growth, but execution still depends on converting awards into backlog and starting studies on schedule. The year-to-date book-to-bill ratio of 1.00 also shows that the first-half recovery was balanced rather than decisive.
Image Source: Zacks Investment Research
MEDP currently carries a Zacks Rank #2 (Buy), with a Growth Score of A and a VGM Score of B. Those readings support the stock's growth profile and complement its favorable earnings-revision signal. Still, a Value Score of D and a Momentum Score of C argue for close attention to valuation, backlog conversion and the durability of bookings before drawing a firmer conclusion.
You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
California State Teachers Retirement System lifted its position in Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report) by 22.1% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 26,042 shares of the company’s stock after buying an additional 4,719 shares during the quarter. California State Teachers Retirement System owned approximately 0.09% of Medpace worth $12,505,000 at the end of the most recent quarter.
Other hedge funds also recently bought and sold shares of the company. Geneos Wealth Management Inc. lifted its stake in Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after purchasing an additional 37 shares in the last quarter. Steigerwald Gordon & Koch Inc. bought a new position in shares of Medpace in the fourth quarter worth $30,000. Elyxium Wealth LLC purchased a new stake in shares of Medpace in the fourth quarter worth $30,000. Quarry LP bought a new stake in Medpace during the third quarter valued at $35,000. Finally, Bayban purchased a new position in Medpace during the fourth quarter worth about $44,000. Hedge funds and other institutional investors own 77.98% of the company’s stock.
Medpace Trading Down 0.7% Medpace stock opened at $573.29 on Tuesday. The firm has a market cap of $16.00 billion, a P/E ratio of 33.60, a P/E/G ratio of 2.57 and a beta of 1.15. Medpace Holdings, Inc. has a 1-year low of $373.00 and a 1-year high of $677.90. The firm has a 50-day moving average of $510.42 and a 200-day moving average of $492.78.
Medpace (NASDAQ:MEDP – Get Free Report) last announced its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.98 by $0.27. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The company had revenue of $707.33 million for the quarter, compared to the consensus estimate of $689.51 million. During the same quarter in the previous year, the business earned $3.10 EPS. Medpace’s revenue was up 17.2% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Research analysts forecast that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.
Insider Activity at Medpace In other news, VP Susan E. Burwig sold 7,500 shares of the firm’s stock in a transaction dated Tuesday, July 28th. The shares were sold at an average price of $600.00, for a total value of $4,500,000.00. Following the completion of the sale, the vice president directly owned 62,984 shares of the company’s stock, valued at approximately $37,790,400. This trade represents a 10.64% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, General Counsel Stephen P. Ewald sold 16,349 shares of the firm’s stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the completion of the sale, the general counsel directly owned 20,343 shares of the company’s stock, valued at approximately $9,154,350. This represents a 44.56% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 31,087 shares of company stock worth $16,203,054 over the last quarter. Corporate insiders own 20.50% of the company’s stock.
Analyst Upgrades and Downgrades MEDP has been the subject of a number of research analyst reports. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and set a $535.00 price target on shares of Medpace in a research report on Thursday, July 23rd. Wall Street Zen lowered shares of Medpace from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Truist Financial raised their price objective on shares of Medpace from $462.00 to $609.00 and gave the company a “hold” rating in a research report on Friday, July 24th. Jefferies Financial Group cut Medpace from a “buy” rating to a “hold” rating and increased their target price for the company from $490.00 to $515.00 in a research note on Tuesday, July 7th. Finally, Mizuho increased their price objective on Medpace from $586.00 to $665.00 and gave the company an “outperform” rating in a research report on Friday, July 24th. Two investment analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the stock. According to MarketBeat, Medpace presently has an average rating of “Hold” and an average price target of $584.18.
Read Our Latest Stock Report on MEDP
About Medpace (Free Report)
Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.
Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.
Read More Five stocks we like better than Medpace SpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control Why Rare Earth Processing Could Be the Real 2027 Opportunity The S&P 493 Are Staging a Comeback—This Value ETF Offers Broad Exposure TSMC Insiders Are Buying the Pullback—But Is the Signal as Bullish as It Looks?
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINECalifornia State Teachers Retirement System Trims Holdings in The J. M. Smucker Company $SJM
NEXT HEADLINE »California State Teachers Retirement System Boosts Stock Position in BridgeBio Pharma, Inc. $BBIO
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.
The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.
Zacks Premium includes access to the Zacks Style Scores as well.
What are the Zacks Style Scores? Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.
Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the score, the better chance the stock will outperform; an A is better than a B, a B is better than a C, and so on.
The Style Scores are broken down into four categories:
Value ScoreFor value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks.
Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.
Momentum ScoreMomentum investors, who live by the saying "the trend is your friend," are most interested in taking advantage of upward or downward trends in a stock's price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks.
VGM ScoreIf you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.
Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +23.94% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.
That's where the Style Scores come in.
To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.
The direction of a stock's earnings estimate revisions should always be a key factor when choosing which stocks to buy, since the Scores were created to work together with the Zacks Rank.
Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Medpace (MEDP - Free Report) Medpace Holdings, Inc. is a global clinical contract research organization (CRO) delivering full-service Phase I-IV drug and device development support, including protocol and project management, regulatory affairs, clinical monitoring, data management/analysis, pharmacovigilance, submission support, and specialized services such as bioanalytical labs and medical imaging. The company is headquartered in Cincinnati, OH, and employs approximately 6,200 people across 46 countries as of fiscal 2025.
MEDP is a #2 (Buy) on the Zacks Rank, with a VGM Score of B.
Momentum investors should take note of this Medical stock. MEDP has a Momentum Style Score of A, and shares are up 3.5% over the past four weeks.
For fiscal 2026, five analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.47 to $17.51 per share. MEDP boasts an average earnings surprise of +10.2%.
With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, MEDP should be on investors' short list.
First Trust Advisors LP reduced its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report) by 4.4% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 64,677 shares of the company’s stock after selling 3,008 shares during the quarter. First Trust Advisors LP owned about 0.23% of Medpace worth $31,057,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. AQR Capital Management LLC lifted its holdings in Medpace by 31.6% during the fourth quarter. AQR Capital Management LLC now owns 1,349,703 shares of the company’s stock worth $758,061,000 after buying an additional 324,293 shares during the period. Wasatch Advisors LP lifted its holdings in shares of Medpace by 14.0% during the 2nd quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock valued at $296,853,000 after purchasing an additional 116,354 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Medpace by 3.8% in the 4th quarter. Geode Capital Management LLC now owns 667,298 shares of the company’s stock worth $374,836,000 after purchasing an additional 24,625 shares in the last quarter. Invesco Ltd. boosted its position in shares of Medpace by 18.9% in the 3rd quarter. Invesco Ltd. now owns 537,407 shares of the company’s stock worth $276,313,000 after purchasing an additional 85,517 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership grew its stake in Medpace by 19.4% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 375,033 shares of the company’s stock worth $210,637,000 after buying an additional 60,883 shares during the last quarter. 77.98% of the stock is currently owned by institutional investors.
Medpace Stock Performance Shares of MEDP stock opened at $570.97 on Wednesday. Medpace Holdings, Inc. has a fifty-two week low of $373.00 and a fifty-two week high of $677.90. The firm has a market capitalization of $15.94 billion, a PE ratio of 33.47, a P/E/G ratio of 2.63 and a beta of 1.15. The stock’s 50-day simple moving average is $498.48 and its 200-day simple moving average is $493.41.
Medpace (NASDAQ:MEDP – Get Free Report) last released its earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, topping analysts’ consensus estimates of $3.98 by $0.27. The firm had revenue of $707.33 million during the quarter, compared to the consensus estimate of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The company’s revenue was up 17.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Sell-side analysts forecast that Medpace Holdings, Inc. will post 17.55 earnings per share for the current year.
Insider Transactions at Medpace In other Medpace news, General Counsel Stephen P. Ewald sold 16,349 shares of Medpace stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the completion of the sale, the general counsel directly owned 20,343 shares in the company, valued at approximately $9,154,350. The trade was a 44.56% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Corporate insiders own 20.50% of the company’s stock.
Wall Street Analysts Forecast Growth MEDP has been the topic of several recent analyst reports. Wall Street Zen lowered Medpace from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a $535.00 price target on shares of Medpace in a report on Thursday, July 23rd. BMO Capital Markets upped their price objective on shares of Medpace from $400.00 to $600.00 and gave the company a “market perform” rating in a report on Friday. Jefferies Financial Group downgraded shares of Medpace from a “buy” rating to a “hold” rating and upped their price objective for the company from $490.00 to $515.00 in a report on Tuesday, July 7th. Finally, Royal Bank Of Canada increased their price objective on shares of Medpace from $484.00 to $692.00 and gave the company an “outperform” rating in a research report on Friday. Two research analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $584.18.
Get Our Latest Stock Analysis on MEDP
About Medpace (Free Report)
Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.
Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.
Featured Stories Five stocks we like better than Medpace These 3 Stocks Have Soared in 2026—Can They Keep Climbing? Hasbro’s Earnings Beat Shows Why This Is No Longer Just a Toy Story Rambus: Another AI Phoenix Ready to Rise From the Ashes of Correction Chips & Clips: Memory Tariffs Rewire Tech Supply Chains
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEFirst Trust Advisors LP Acquires 211,010 Shares of KBR, Inc. $KBR
American Capital Management Inc. lessened its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report) by 2.9% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 217,947 shares of the company’s stock after selling 6,427 shares during the period. Medpace accounts for 5.6% of American Capital Management Inc.’s holdings, making the stock its biggest holding. American Capital Management Inc. owned about 0.76% of Medpace worth $104,656,000 as of its most recent SEC filing.
Several other institutional investors also recently modified their holdings of MEDP. NewEdge Advisors LLC raised its position in Medpace by 22.1% during the 1st quarter. NewEdge Advisors LLC now owns 1,048 shares of the company’s stock worth $319,000 after purchasing an additional 190 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in Medpace by 3.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 81,817 shares of the company’s stock worth $24,929,000 after buying an additional 3,010 shares during the period. Geneos Wealth Management Inc. grew its position in shares of Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after buying an additional 37 shares during the last quarter. Sivia Capital Partners LLC bought a new stake in shares of Medpace in the 2nd quarter valued at about $296,000. Finally, M&T Bank Corp increased its stake in shares of Medpace by 3.4% in the second quarter. M&T Bank Corp now owns 939 shares of the company’s stock valued at $295,000 after buying an additional 31 shares during the period. Institutional investors own 77.98% of the company’s stock.
Medpace Stock Performance Shares of MEDP stock opened at $589.37 on Tuesday. The company has a market cap of $16.45 billion, a P/E ratio of 34.55, a PEG ratio of 2.68 and a beta of 1.15. The stock has a 50 day simple moving average of $495.46 and a two-hundred day simple moving average of $493.70. Medpace Holdings, Inc. has a fifty-two week low of $373.00 and a fifty-two week high of $677.90.
Medpace (NASDAQ:MEDP – Get Free Report) last issued its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.98 by $0.27. The firm had revenue of $707.33 million for the quarter, compared to analyst estimates of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The company’s revenue was up 17.2% compared to the same quarter last year. During the same period in the previous year, the firm earned $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, research analysts predict that Medpace Holdings, Inc. will post 17.59 earnings per share for the current year.
Wall Street Analyst Weigh In MEDP has been the subject of a number of analyst reports. Royal Bank Of Canada raised their price objective on Medpace from $484.00 to $692.00 and gave the stock an “outperform” rating in a research report on Friday. Jefferies Financial Group cut Medpace from a “buy” rating to a “hold” rating and upped their target price for the company from $490.00 to $515.00 in a report on Tuesday, July 7th. Weiss Ratings reissued a “hold (c+)” rating on shares of Medpace in a research report on Thursday, July 2nd. Mizuho raised their price target on shares of Medpace from $586.00 to $665.00 and gave the stock an “outperform” rating in a report on Friday. Finally, Wall Street Zen lowered shares of Medpace from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Two research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Medpace presently has a consensus rating of “Hold” and a consensus price target of $560.92.
View Our Latest Stock Analysis on Medpace
Insider Buying and Selling at Medpace In other news, General Counsel Stephen P. Ewald sold 16,349 shares of Medpace stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $450.00, for a total value of $7,357,050.00. Following the completion of the sale, the general counsel owned 20,343 shares in the company, valued at $9,154,350. The trade was a 44.56% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 20.50% of the stock is owned by corporate insiders.
About Medpace (Free Report)
Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.
Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.
See Also Five stocks we like better than Medpace AirJoule’s Kubota Deal Is a Major Validation—But the Hard Part Comes Next Dividend Stocks May Be the Quiet Rotation Trade Investors Are Missing Now Refiner Stocks Are Near Record Highs—Can Iran-Driven Margins Keep Them There? Verizon May Be an AI Infrastructure Stock Hiding in Plain Sight Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report).
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEDynamo Internacional Gestao DE Recursos LTDA. Purchases 4,806,348 Shares of Nu Holdings Ltd. $NU
NEXT HEADLINE »RBC Bearings Incorporated $RBC is American Capital Management Inc.’s 3rd Largest Position
Growth stocks are attractive to many investors, as above-average financial growth helps these stocks easily grab the market's attention and produce exceptional returns. But finding a great growth stock is not easy at all.
In addition to volatility, these stocks carry above-average risk by their very nature. Also, one could end up losing from a stock whose growth story is actually over or nearing its end.
However, it's pretty easy to find cutting-edge growth stocks with the help of the Zacks Growth Style Score (part of the Zacks Style Scores system), which looks beyond the traditional growth attributes to analyze a company's real growth prospects.
Medpace (MEDP - Free Report) is one such stock that our proprietary system currently recommends. The company not only has a favorable Growth Score, but also carries a top Zacks Rank.
Studies have shown that stocks with the best growth features consistently outperform the market. And for stocks that have a combination of a Growth Score of A or B and a Zacks Rank #1 (Strong Buy) or 2 (Buy), returns are even better.
While there are numerous reasons why the stock of this provider of outsourced clinical development services is a great growth pick right now, we have highlighted three of the most important factors below:
Earnings GrowthEarnings growth is arguably the most important factor, as stocks exhibiting exceptionally surging profit levels tend to attract the attention of most investors. For growth investors, double-digit earnings growth is highly preferable, as it is often perceived as an indication of strong prospects (and stock price gains) for the company under consideration.
While the historical EPS growth rate for Medpace is 31.2%, investors should actually focus on the projected growth. The company's EPS is expected to grow 13.5% this year, crushing the industry average, which calls for EPS growth of 12.8%.
Cash Flow GrowthWhile cash is the lifeblood of any business, higher-than-average cash flow growth is more important and beneficial for growth-oriented companies than for mature companies. That's because, growth in cash flow enables these companies to expand their businesses without depending on expensive outside funds.
Right now, year-over-year cash flow growth for Medpace is 10.5%, which is higher than many of its peers. In fact, the rate compares to the industry average of 1.2%.
While investors should actually consider the current cash flow growth, it's worth taking a look at the historical rate too for putting the current reading into proper perspective. The company's annualized cash flow growth rate has been 23% over the past 3-5 years versus the industry average of 10.8%.
Promising Earnings Estimate RevisionsSuperiority of a stock in terms of the metrics outlined above can be further validated by looking at the trend in earnings estimate revisions. A positive trend is of course favorable here. Empirical research shows that there is a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
The current-year earnings estimates for Medpace have been revising upward. The Zacks Consensus Estimate for the current year has surged 3.2% over the past month.
Bottom LineWhile the overall earnings estimate revisions have made Medpace a Zacks Rank #2 stock, it has earned itself a Growth Score of A based on a number of factors, including the ones discussed above.
You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
This combination positions Medpace well for outperformance, so growth investors may want to bet on it.
Dimensional Fund Advisors LP cut its position in Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report) by 3.0% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 348,485 shares of the company’s stock after selling 10,865 shares during the period. Dimensional Fund Advisors LP owned about 1.22% of Medpace worth $167,300,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently made changes to their positions in MEDP. Geneos Wealth Management Inc. lifted its holdings in shares of Medpace by 64.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after purchasing an additional 37 shares in the last quarter. Steigerwald Gordon & Koch Inc. bought a new stake in shares of Medpace during the fourth quarter worth $30,000. Elyxium Wealth LLC acquired a new position in Medpace in the 4th quarter worth $30,000. Quarry LP acquired a new position in Medpace in the 3rd quarter worth $35,000. Finally, Bayban bought a new position in Medpace during the 4th quarter worth about $44,000. 77.98% of the stock is owned by institutional investors.
Insiders Place Their Bets In other Medpace news, General Counsel Stephen P. Ewald sold 16,349 shares of the firm’s stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $450.00, for a total value of $7,357,050.00. Following the completion of the transaction, the general counsel directly owned 20,343 shares in the company, valued at $9,154,350. This trade represents a 44.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 20.50% of the stock is currently owned by corporate insiders.
Medpace Price Performance Medpace stock opened at $601.38 on Friday. The firm has a 50-day moving average of $492.09 and a 200-day moving average of $494.49. Medpace Holdings, Inc. has a one year low of $373.00 and a one year high of $677.90. The company has a market cap of $17.18 billion, a price-to-earnings ratio of 35.25, a P/E/G ratio of 2.93 and a beta of 1.15.
Medpace (NASDAQ:MEDP – Get Free Report) last released its earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.98 by $0.27. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The business had revenue of $707.33 million for the quarter, compared to the consensus estimate of $689.51 million. During the same quarter in the previous year, the business earned $3.10 earnings per share. Medpace’s quarterly revenue was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, sell-side analysts expect that Medpace Holdings, Inc. will post 17.59 earnings per share for the current year.
Key Stories Impacting Medpace Here are the key news stories impacting Medpace this week:
Positive Sentiment: Medpace reported stronger-than-expected Q2 results, with EPS of $4.25 topping estimates and revenue of $707.3 million exceeding forecasts, reinforcing momentum in the business. MarketWatch article Positive Sentiment: The company raised FY 2026 guidance to EPS of $17.25-$17.95 and revenue of about $2.8 billion-$2.9 billion, signaling confidence in continued growth and backlog conversion. Benzinga article Positive Sentiment: Bookings and backlog trends improved, with commentary highlighting a rebound in the net book-to-bill ratio and better revenue visibility, which supports investor optimism about future quarters. Seeking Alpha article Neutral Sentiment: Truist raised its price target to $609 from $462 but kept a hold rating, while Robert W. Baird lifted its target to $624 and maintained a neutral stance, suggesting analysts see upside but are not turning fully bullish. Benzinga article Neutral Sentiment: The stock’s move to a 52-week high reflects strong recent performance, but one Zacks note questioned whether the rally can continue, indicating the market may now be weighing valuation against the improved fundamentals. Zacks article Analysts Set New Price Targets MEDP has been the subject of a number of research reports. BMO Capital Markets increased their price objective on Medpace from $400.00 to $600.00 and gave the stock a “market perform” rating in a report on Friday. Royal Bank Of Canada upped their price target on Medpace from $484.00 to $692.00 and gave the stock an “outperform” rating in a research report on Friday. Jefferies Financial Group cut shares of Medpace from a “buy” rating to a “hold” rating and raised their price target for the stock from $490.00 to $515.00 in a research note on Tuesday, July 7th. TD Cowen lifted their price objective on shares of Medpace from $419.00 to $492.00 and gave the company a “hold” rating in a report on Friday. Finally, Robert W. Baird lifted their price objective on shares of Medpace from $547.00 to $624.00 and gave the company a “neutral” rating in a report on Friday. Two research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Medpace currently has an average rating of “Hold” and an average target price of $560.92.
Check Out Our Latest Analysis on MEDP
Medpace Profile (Free Report)
Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.
Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.
Further Reading Five stocks we like better than Medpace Telecom Earnings Reveal a Sector That Finally Looks Healthier Defense Earnings Show Readiness Now and Modernization Ahead Why Palantir Investors Aren’t Panicking While the Rest of AI Sells Off MarketBeat Week in Review – 07/20- 07/24
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINESTERIS plc $STE Shares Acquired by Arrowstreet Capital Limited Partnership
NEXT HEADLINE »Dimensional Fund Advisors LP Increases Stock Holdings in First Hawaiian, Inc. $FHB
Arrowstreet Capital Limited Partnership grew its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report) by 5.5% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 395,769 shares of the company’s stock after buying an additional 20,736 shares during the quarter. Arrowstreet Capital Limited Partnership owned 1.39% of Medpace worth $190,044,000 at the end of the most recent reporting period.
Other large investors have also recently made changes to their positions in the company. Gibbs Wealth Management raised its holdings in shares of Medpace by 210.7% in the 1st quarter. Gibbs Wealth Management now owns 1,221 shares of the company’s stock valued at $586,000 after purchasing an additional 828 shares in the last quarter. Militia Capital Management LLC purchased a new position in Medpace during the first quarter valued at approximately $3,389,000. NewEdge Wealth LLC increased its holdings in Medpace by 1,044.6% during the first quarter. NewEdge Wealth LLC now owns 49,777 shares of the company’s stock valued at $23,902,000 after buying an additional 45,428 shares during the period. Balefire LLC boosted its position in Medpace by 6.1% during the first quarter. Balefire LLC now owns 451 shares of the company’s stock valued at $217,000 after purchasing an additional 26 shares in the last quarter. Finally, Swiss National Bank increased its position in shares of Medpace by 0.4% during the first quarter. Swiss National Bank now owns 44,480 shares of the company’s stock worth $21,359,000 after purchasing an additional 160 shares in the last quarter. 77.98% of the stock is owned by hedge funds and other institutional investors.
Insiders Place Their Bets In other news, General Counsel Stephen P. Ewald sold 16,349 shares of the stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the transaction, the general counsel directly owned 20,343 shares in the company, valued at $9,154,350. This represents a 44.56% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 20.50% of the company’s stock.
Medpace Stock Down 0.7% MEDP opened at $601.38 on Friday. The company has a market cap of $17.18 billion, a PE ratio of 35.25, a P/E/G ratio of 2.96 and a beta of 1.15. The business has a 50 day moving average price of $492.09 and a two-hundred day moving average price of $494.49. Medpace Holdings, Inc. has a 52 week low of $373.00 and a 52 week high of $677.90.
Medpace (NASDAQ:MEDP – Get Free Report) last issued its earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, topping the consensus estimate of $3.98 by $0.27. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The company had revenue of $707.33 million for the quarter, compared to analyst estimates of $689.51 million. During the same period in the previous year, the firm earned $3.10 EPS. The business’s revenue was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, sell-side analysts expect that Medpace Holdings, Inc. will post 17.45 EPS for the current fiscal year.
Key Medpace News Here are the key news stories impacting Medpace this week:
Positive Sentiment: Medpace reported stronger-than-expected Q2 results, with EPS of $4.25 topping estimates and revenue of $707.3 million exceeding forecasts, reinforcing momentum in the business. MarketWatch article Positive Sentiment: The company raised FY 2026 guidance to EPS of $17.25-$17.95 and revenue of about $2.8 billion-$2.9 billion, signaling confidence in continued growth and backlog conversion. Benzinga article Positive Sentiment: Bookings and backlog trends improved, with commentary highlighting a rebound in the net book-to-bill ratio and better revenue visibility, which supports investor optimism about future quarters. Seeking Alpha article Neutral Sentiment: Truist raised its price target to $609 from $462 but kept a hold rating, while Robert W. Baird lifted its target to $624 and maintained a neutral stance, suggesting analysts see upside but are not turning fully bullish. Benzinga article Neutral Sentiment: The stock’s move to a 52-week high reflects strong recent performance, but one Zacks note questioned whether the rally can continue, indicating the market may now be weighing valuation against the improved fundamentals. Zacks article Analyst Ratings Changes Several research firms have recently commented on MEDP. Wall Street Zen downgraded shares of Medpace from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Royal Bank Of Canada boosted their price objective on Medpace from $484.00 to $692.00 and gave the company an “outperform” rating in a report on Friday. Jefferies Financial Group lowered Medpace from a “buy” rating to a “hold” rating and raised their target price for the stock from $490.00 to $515.00 in a report on Tuesday, July 7th. Truist Financial upped their price objective on Medpace from $462.00 to $609.00 and gave the stock a “hold” rating in a research report on Friday. Finally, Robert W. Baird raised their price objective on shares of Medpace from $547.00 to $624.00 and gave the stock a “neutral” rating in a research note on Friday. Two investment analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $560.92.
Read Our Latest Report on Medpace
Medpace Profile (Free Report)
Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.
Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.
Featured Articles Five stocks we like better than Medpace AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Plugging In: How Kinder Morgan Powers Up Profits
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEABN Amro Investment Solutions Has $1.95 Million Stake in Mitsubishi UFJ Financial Group, Inc. $MUFG
NEXT HEADLINE »Arrowstreet Capital Limited Partnership Increases Stock Holdings in HubSpot, Inc. $HUBS
Medpace Holdings demonstrates strong Q2 2026 net new business awards, with a 1.13x net book-to-bill and $3.0B backlog. Oncology bookings are robust, while cardiometabolic awards have declined; management expects mix normalization over the next year. Guidance is lifted on improved RFP trends, biotech funding breadth, and moderated cancellations, supporting growth momentum into 2027.
A strong stock as of late has been Medpace (MEDP - Free Report) . Shares have been marching higher, with the stock up 16.5% over the past month. The stock hit a new 52-week high of $677.9 in the previous session. Medpace has gained 7.9% since the start of the year compared to the -0.1% gain for the Zacks Medical sector and the -1.8% return for the Zacks Medical Services industry.
What's Driving the Outperformance?The stock has an impressive record of positive earnings surprises, having beaten the Zacks Consensus Estimate in each of the last four quarters. In its last earnings report on July 22, 2026, Medpace reported EPS of $4.25 versus consensus estimate of $4.08 while it beat the consensus revenue estimate by 1.12%.
For the current fiscal year, Medpace is expected to post earnings of $17.12 per share on $2.81 in revenues. This represents a 12.04% change in EPS on a 11.02% change in revenues. For the next fiscal year, the company is expected to earn $18.63 per share on $2.92 in revenues. This represents a year-over-year change of 8.8% and 4.07%, respectively.
Valuation MetricsMedpace may be at a 52-week high right now, but what might the future hold for the stock? A key aspect of this question is taking a look at valuation metrics in order to determine if the company is due for a pullback from this level.
On this front, we can look at the Zacks Style Scores, as these give investors a variety of ways to comb through stocks (beyond looking at the Zacks Rank of a security). These styles are represented by grades running from A to F in the categories of Value, Growth, and Momentum, while there is a combined VGM Score as well. Investors should consider the style scores a valuable tool that can help you to pick the most appropriate Zacks Rank stocks based on their individual investment style.
Medpace has a Value Score of D. The stock's Growth and Momentum Scores are A and B, respectively, giving the company a VGM Score of B.
In terms of its value breakdown, the stock currently trades at 35.4X current fiscal year EPS estimates, which is a premium to the peer industry average of 16X. On a trailing cash flow basis, the stock currently trades at 35.6X versus its peer group's average of 10X. Additionally, the stock has a PEG ratio of 3.01. This isn't enough to put the company in the top echelon of all stocks we cover from a value perspective.
Zacks RankWe also need to consider the stock's Zacks Rank, as this is even more important than the company's VGM Score. Fortunately, Medpace currently has a Zacks Rank of #2 (Buy) thanks to favorable earnings estimate revisions from covering analysts.
Since we recommend that investors select stocks carrying Zacks Rank of 1 (Strong Buy) or 2 (Buy) and Style Scores of A or B, it looks as if Medpace passes the test. Thus, it seems as though Medpace shares could still be poised for more gains ahead.
How Does MEDP Stack Up to the Competition?Shares of MEDP have been soaring, and the company still appears to be a decent choice, but what about the rest of the industry? One industry peer that looks good is CVS Health Corporation (CVS - Free Report) . CVS has a Zacks Rank of #2 (Buy) and a Value Score of A, a Growth Score of C, and a Momentum Score of B.
Earnings were strong last quarter. CVS Health Corporation beat our consensus estimate by 16.29%, and for the current fiscal year, CVS is expected to post earnings of $7.46 per share on revenue of $409 billion.
Shares of CVS Health Corporation have gained 2.1% over the past month, and currently trade at a forward P/E of 14.33X and a P/CF of 7.18X.
The Medical Services industry is in the top 39% of all the industries we have in our universe, so it looks like there are some nice tailwinds for MEDP and CVS, even beyond their own solid fundamental situation.
The clinical contract research organization reported earnings of $4.25, beating the consensus of $3.97.
The company reported sales of $707.33 million, surpassing the consensus of $687.65 million.
Revenues increased 17.2% year over year, representing a backlog conversion rate of 24.1%.
EBITDA climbed 17.6% to $153.4 million, representing 21.7% of total revenue.
Backlog Continues To GrowMeanwhile, the company’s project backlog grew 4.9% year-over-year to over $3.01 billion. Net new business awards hit $795.7 million for the quarter, generating a healthy net book-to-bill ratio of 1.13x.
CEO August Troendle in the earnings conference call said, “Cancellations were well-behaved and supported a record quarter for net bookings. RFPs were up sequentially and year over year, generating high-quality opportunities.”
“Overall, the environment remains constructive into July, and we are making good progress in positioning the business for 2027,” Troendle further commented.
Medpace Raises Fiscal 2026 GuidanceMedpace on Wednesday raised its fiscal 2026 earnings from $16.68-$17.50 per share to $17.25-$17.95 per share compared to the consensus of $16.97.
The company also increased fiscal 2026 revenue guidance from $2.755 billion-$2.855 billion to $2.805 billion-$2.885 billion compared to the consensus of $2.778 billion.
EBITDA is expected to reach between $618.0 million and $642.0 million.
MEDP Stock Price Activity: Medpace Holdings shares were up 14.24% at $603.31 at the time of publication on Thursday, according to Benzinga Pro data.
Photo: Shutterstock
Market News and Data brought to you by Benzinga APIs
Medpace Holdings, Inc. (MEDP) Q2 2026 Earnings Call July 23, 2026 9:00 AM EDT
Company Participants
David Ruhe
August Troendle - CEO, President & Chairman
Kevin Brady - CFO & Treasurer
Conference Call Participants
Charles Rhyee - TD Cowen, Research Division
Michael Cherny - Leerink Partners LLC, Research Division
Ann Hynes - Mizuho Securities USA LLC, Research Division
Jailendra Singh - Truist Securities, Inc., Research Division
Christine Rains - William Blair & Company L.L.C., Research Division
David Windley - Jefferies LLC, Research Division
Ryan Halsted - RBC Capital Markets, Research Division
Eric Coldwell - Robert W. Baird & Co. Incorporated, Research Division
Justin Bowers - Deutsche Bank AG, Research Division
Presentation
Operator
Good day, ladies and gentlemen, and welcome to the Medpace Second Quarter 2026 Earnings Conference Call. [Operator Instructions] As a reminder, this call is being recorded. I would now like to introduce your host for today's conference call, David Ruhe, Medpace's Director of Investor Relations. You may begin.
David Ruhe
Good morning, and thank you for joining Medpace's second quarter 2026 Earnings Conference Call. Also on the call today is our CEO, August Troendle; and our CFO, Kevin Brady. Before we begin, I would like to remind you that our remarks and responses to your questions during this teleconference may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve inherent assumptions with known and unknown risks and uncertainties as well as other important factors that could cause actual results to differ materially from our current expectations. These factors are discussed in our Form 10-K and other filings with the SEC. Please note that we assume no obligation to update forward-looking statements even if estimates change. Accordingly, you should not rely on any of today's forward-looking statements as representing our views as of any date after today.
Medpace Holdings remains a "Buy" as Q2 2026 showed broad metric improvement and an inflection point in growth trajectory. The company's net book-to-Bill ratio rebounded to 1.13x, and backlog conversion rate rose to 24.1%, signaling strong future revenue visibility. Revenue grew 17.2% YoY to $707.3M, with EPS of $4.25 beating expectations; full-year 2026 guidance was raised to $2.805B–$2.885B.
Can Medpace Stock Keep up this Pace?Medpace NASDAQ: MEDP reported double-digit growth in second-quarter revenue and earnings, while management described the business environment as strong and said lower cancellations helped drive record net bookings.
CEO August Troendle said on the company’s second-quarter 2026 earnings call that cancellations were “well-behaved” in the period and supported a record quarter for net bookings. He added that requests for proposals increased both sequentially and year over year, producing what he called “high-quality opportunities.”
Get Medpace alerts:
“Overall, the environment remains constructive into July,” Troendle said. “We are making good progress in positioning the business for 2027.”
Second-Quarter Revenue Rises 17.2% CFO Kevin Brady said Medpace generated second-quarter revenue of $707.3 million, up 17.2% from the year-ago period. Revenue for the first six months of 2026 was $1.41 billion, an increase of 21.7%.
EBITDA for the quarter rose 17.6% to $153.4 million from $130.5 million in the second quarter of 2025. EBITDA margin was 21.7%, compared with 21.6% a year earlier. Year-to-date EBITDA was $302.8 million, up 21.5%, with the EBITDA margin flat at 21.4%.
Brady said the year-to-date margin reflected the impact of higher reimbursable costs, offset primarily by lower employee-related costs.
Net income increased 34.5% to $121.4 million from $90.3 million in the prior-year quarter. Brady attributed the stronger net income growth relative to EBITDA growth primarily to a lower effective tax rate and higher interest income. Diluted earnings per share were $4.25, compared with $3.10 in the second quarter of 2025.
For the first six months of 2026, net income was $245.2 million, up 19.7% from $204.9 million in the comparable prior-year period. Year-to-date diluted EPS was $8.53, compared with $6.79.
Bookings Reach Record Level as Cancellations Improve Net new business awards entering backlog increased 28.2% year over year to $795.7 million, producing a net book-to-bill ratio of 1.13. Ending backlog as of June 30 was approximately $3 billion, up 4.9% from the prior year. Brady said Medpace expects roughly $1.96 billion of backlog to convert to revenue over the next 12 months.
Backlog conversion in the second quarter was 24.1% of beginning backlog. Brady also said Medpace’s top five and top 10 customers represented approximately 31% and 40%, respectively, of revenue over the last 12 months.
In response to analyst questions, Troendle said the improvement in net bookings from the first quarter was driven more by reduced cancellations than by gross bookings. He said cancellations had fallen to a “very good level,” though not an unusually low one.
“Cancellations are always a wild card,” Troendle said, adding that the company has limited ability to predict them. He said Medpace has been careful about what it recognizes in backlog when programs include interim analyses, regulatory decisions or other points that could affect whether a study continues.
Therapeutic Mix Shifts Back Toward Oncology Troendle said recent growth among Medpace’s top customers had been driven “quite a bit” by metabolic work, including large programs within the company’s top five customers. However, he said the mix of new opportunities has shifted in recent quarters.
“Oncology has come back quite a bit in terms of both our award notifications” and bookings, Troendle said. He said oncology represented more than half of overall bookings and award notifications in the second quarter, while cardiometabolic had “dropped off quite a bit” in new award notifications.
Troendle said he expects the company’s therapeutic mix to move back toward historical averages over the next year or so, with oncology regaining a larger position in the mix. He said some of the very large metabolic programs are reducing, and new opportunities in that area are not as large as they were a year ago.
Management also addressed questions about backlog conversion and whether metabolic programs were responsible for a higher burn rate. Troendle said he would “challenge the very premise” that metabolic programs were the primary driver of increased conversion, noting that Medpace often limits backlog recognition beyond interim decision points across many types of programs, including oncology.
Cash Flow, Buybacks and 2026 Guidance Medpace generated $162 million in cash flow from operating activities in the quarter, and Brady said net days sales outstanding were negative 59.6 days. The company ended the quarter with $502.7 million in cash.
During the second quarter, Medpace repurchased approximately 706,000 shares for $294.7 million. As of June 30, the company had $527 million remaining under its share repurchase authorization.
Medpace updated its full-year 2026 guidance. The company now expects:
Total revenue: $2.805 billion to $2.885 billion, representing growth of 10.9% to 14% over 2025 revenue of $2.53 billion. EBITDA: $618 million to $642 million, representing growth of 10.8% to 15.1% compared with 2025 EBITDA of $557.7 million. Net income: $494 million to $514 million. Diluted EPS: $17.25 to $17.95. Brady said the guidance assumes a full-year effective tax rate of 19% to 19.5%, interest income of $21.1 million and no additional share repurchases. The forecast is based on foreign exchange rates as of June 30, 2026.
Management Points to Stronger Funding Environment On the broader market backdrop, Troendle said the environment has strengthened over the last several quarters. He said clients with recent funding are generating more opportunities and moving forward with programs.
Asked about competition and pricing, Troendle said he did not see notable changes in competitive dynamics. He said the profile of opportunities has moved back toward oncology being the largest category, compared with the metabolic drivers seen about a year ago.
Troendle also said the company had implemented changes intended to improve win rates after recognizing that its win rate in 2025 had been lower than in prior years. He declined to provide details on those competitive changes but said they may have influenced the company’s strong win rate in the first quarter.
On labor, Troendle said Medpace is “in a good place,” helped by continued low employee turnover. He said the company expects high-single-digit employee growth this year and suspects that trend will continue next year. Employee growth has been strongest in the U.S., followed by Asia Pacific, including India.
About Medpace (NASDAQ:MEDP)Medpace Holdings, Inc NASDAQ: MEDP is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.
Medpace's core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Should You Invest $1,000 in Medpace Right Now?Before you consider Medpace, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medpace wasn't on the list.
While Medpace currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Medpace (MEDP - Free Report) came out with quarterly earnings of $4.25 per share, beating the Zacks Consensus Estimate of $4.08 per share. This compares to earnings of $3.1 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of +4.17%. A quarter ago, it was expected that this provider of outsourced clinical development services would post earnings of $3.74 per share when it actually produced earnings of $4.28, delivering a surprise of +14.44%.
Over the last four quarters, the company has surpassed consensus EPS estimates four times.
Medpace, which belongs to the Zacks Medical Services industry, posted revenues of $707.33 million for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 1.12%. This compares to year-ago revenues of $603.31 million. The company has topped consensus revenue estimates four times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Medpace shares have lost about 5.3% since the beginning of the year versus the S&P 500's gain of 9.7%.
What's Next for Medpace?While Medpace has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Medpace was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $4.22 on $694.23 million in revenues for the coming quarter and $17.04 on $2.79 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical Services is currently in the top 37% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Avantor, Inc. (AVTR - Free Report) , another stock in the same industry, has yet to report results for the quarter ended June 2026. The results are expected to be released on July 29.
This company is expected to post quarterly earnings of $0.19 per share in its upcoming report, which represents a year-over-year change of -20.8%. The consensus EPS estimate for the quarter has been revised 0.1% higher over the last 30 days to the current level.
Avantor, Inc.'s revenues are expected to be $1.62 billion, down 3.5% from the year-ago quarter.
CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial results for the second quarter ended June 30, 2026. Second Quarter 2026 Financial Results Revenue for the three months ended June 30, 2026 increased 17.2% to $707.3 million, compared to $603.3 million for the comparable prior-year period. On a constant currency basis, revenue for the second quarter of 2026 increased 17.2% compared to the second quarter of 2025. Backlog as of June 30, 2026 in.
Investors.com will undergo scheduled maintenance from 10:00 PM ET to 2:00 AM ET and some features may be unavailable. We apologize for any inconvenience.
Store
SubscribeSign In
My Subscriptions
Founder's ClubSwingTraderLeaderboardMarketSurgeeIBDIBD DigitalIBD LiveCustomer Center
My Stock Lists
Email Preferences
Help & Support
Sign Out
Search stocks or keywords
Sections
My IBD
MARKET TREND
STOCK LISTS
STOCK RESEARCH
NEWSECONOMY
VIDEOS & PODCASTS
HOW TO INVESTEDUCATIONAL RESOURCESStoreMy Products
Founder's ClubSwingTraderLeaderboardMarketSurgeeIBDIBD DigitalIBD Live
Recently Searched
Newly Public Memory-Chip Maker SK Hynix Soars Nearly 14%, Leads 18 To Today's Best Stock Lists
Super Micro Soars Late On Booming Margins, Orders; Dell, HP Enterprise Also Rally
Stock Market Rally Defies Rising Oil, Bond Yields; Chips Lead As Seagate, Micron Make Bullish Moves Medpace Holdings (MEDP) stock surged by double digits late Wednesday, helped by a big bookings beat, rebounding from a poor start to the year. The contract research organization, or CRO, put up a book-to-bill ratio of 1.13x, easily above expectations for 0.95x to 1.01x, according to Leerink Partners analyst Michael Cherny. That means Medpace received more new orders than it…
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.
The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.
Zacks Premium includes access to the Zacks Style Scores as well.
What are the Zacks Style Scores? Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.
Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value ScoreFor value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks.
Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.
Momentum ScoreMomentum trading is all about taking advantage of upward or downward trends in a stock's price or earnings outlook, and these investors live by the saying "the trend is your friend." The Momentum Style Score can pinpoint good times to build a position in a stock, using factors like one-week price change and the monthly percentage change in earnings estimates.
VGM ScoreIf you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.
How Style Scores Work with the Zacks Rank A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.
It's highly successful, with #1 (Strong Buy) stocks producing an unmatched +23.94% average annual return since 1988. That's more than double the S&P 500. But because of the large number of stocks we rate, there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.
That's where the Style Scores come in.
To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.
The direction of a stock's earnings estimate revisions should always be a key factor when choosing which stocks to buy, since the Scores were created to work together with the Zacks Rank.
Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Medpace (MEDP - Free Report) Medpace Holdings, Inc. is a global clinical contract research organization (CRO) delivering full-service Phase I-IV drug and device development support, including protocol and project management, regulatory affairs, clinical monitoring, data management/analysis, pharmacovigilance, submission support, and specialized services such as bioanalytical labs and medical imaging. The company is headquartered in Cincinnati, OH, and employs approximately 6,200 people across 46 countries as of fiscal 2025.
MEDP is a #2 (Buy) on the Zacks Rank, with a VGM Score of B.
Additionally, the company could be a top pick for growth investors. MEDP has a Growth Style Score of A, forecasting year-over-year earnings growth of 11.5% for the current fiscal year.
One analyst revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.00 to $17.04 per share. MEDP also boasts an average earnings surprise of +10%.
With a solid Zacks Rank and top-tier Growth and VGM Style Scores, MEDP should be on investors' short list.
Investors interested in Medical Services stocks are likely familiar with Concentra Group (CON - Free Report) and Medpace (MEDP - Free Report) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.
Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The Zacks Rank is a proven strategy that targets companies with positive earnings estimate revision trends, while our Style Scores work to grade companies based on specific traits.
Right now, Concentra Group is sporting a Zacks Rank of #2 (Buy), while Medpace has a Zacks Rank of #3 (Hold). The Zacks Rank favors stocks that have recently seen positive revisions to their earnings estimates, so investors should rest assured that CON has an improving earnings outlook. But this is just one factor that value investors are interested in.
Value investors also tend to look at a number of traditional, tried-and-true figures to help them find stocks that they believe are undervalued at their current share price levels.
Our Value category grades stocks based on a number of key metrics, including the tried-and-true P/E ratio, the P/S ratio, earnings yield, and cash flow per share, as well as a variety of other fundamentals that value investors frequently use.
CON currently has a forward P/E ratio of 20.30, while MEDP has a forward P/E of 31.47. We also note that CON has a PEG ratio of 1.41. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. MEDP currently has a PEG ratio of 2.72.
Another notable valuation metric for CON is its P/B ratio of 9.19. The P/B ratio pits a stock's market value against its book value, which is defined as total assets minus total liabilities. For comparison, MEDP has a P/B of 25.59.
These are just a few of the metrics contributing to CON's Value grade of B and MEDP's Value grade of D.
CON stands above MEDP thanks to its solid earnings outlook, and based on these valuation figures, we also feel that CON is the superior value option right now.
In the latest close session, Medpace (MEDP - Free Report) was down 1.49% at $530.19. The stock trailed the S&P 500, which registered a daily loss of 0.79%. At the same time, the Dow lost 0.26%, and the tech-heavy Nasdaq lost 1.55%.
Shares of the provider of outsourced clinical development services have appreciated by 15.17% over the course of the past month, outperforming the Medical sector's gain of 5.5%, and the S&P 500's gain of 4.28%.
The upcoming earnings release of Medpace will be of great interest to investors. The company's earnings report is expected on July 22, 2026. The company's upcoming EPS is projected at $4.08, signifying a 31.61% increase compared to the same quarter of the previous year. Meanwhile, our latest consensus estimate is calling for revenue of $699.51 million, up 15.95% from the prior-year quarter.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $17.04 per share and revenue of $2.79 billion, indicating changes of +11.52% and +10.32%, respectively, compared to the previous year.
Investors should also note any recent changes to analyst estimates for Medpace. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Medpace is currently sporting a Zacks Rank of #3 (Hold).
Looking at its valuation, Medpace is holding a Forward P/E ratio of 31.59. For comparison, its industry has an average Forward P/E of 15.5, which means Medpace is trading at a premium to the group.
We can additionally observe that MEDP currently boasts a PEG ratio of 2.73. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. MEDP's industry had an average PEG ratio of 1.44 as of yesterday's close.
The Medical Services industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 109, positioning it in the top 45% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
On July 07, 2026, Medpace Holdings Inc (MEDP) shares fell 3.4% today to a current price of $546.29. The stock has experienced significant volatility, trading wi
Key Takeaways Medpace sees uneven trial demand, with metabolic programs steadier than oncology and cardiovascular.MEDP says awards take three to five quarters to convert, extending the path from pipeline to revenue.Medpace maintained solid EBITDA margins as AI spending is expected to outweigh savings through 2026-2027. Medpace Holdings, Inc. (MEDP - Free Report) offers a focused view of how clinical research organization demand is changing in 2026.
The company’s growth story is not just about trial volume. It also turns on which therapeutic areas are holding up, how quickly awards convert to revenues, and whether technology spending can improve productivity later.
Medpace Shows a Split in Trial DemandDemand across Medpace’s book is becoming more uneven by therapeutic area. Metabolic and GLP-1 programs have historically carried lower cancellation rates, giving that work a stabilizing role in backlog quality and utilization.
Oncology and cardiovascular have been the larger sources of recent cancellations. That matters because both remain important pieces of Medpace’s clinical-development base, and pressure in those areas can weigh on forward visibility even when other categories remain steadier.
The same theme is relevant across the broader clinical services group. IQVIA Holdings Inc. (IQV - Free Report) , which provides clinical research services, healthcare intelligence and technology solutions, is another name investors often watch when trial starts and sponsor spending patterns shift.
MEDP Awards Point to a Longer Conversion CycleMedpace’s early award signals are not translating into immediate revenues. Initial award notifications and win rates have improved, but many awards remain in pre-backlog before moving into active projects.
The timing gap is meaningful. Awards can take three to five quarters to start, which means improved pipeline activity may support later-period growth rather than near-term acceleration.
That delayed conversion cycle helps explain why backlog can support continuity without proving a sharp rebound. Medpace expects roughly $1.9 billion to $1.94 billion of backlog to convert into revenues over the next 12 months, but first-quarter net book-to-bill was 0.88X.
Image Source: Zacks Investment Research
Medpace Margins Benefit From Full-Service FocusMedpace’s full-service model has helped protect profitability through mix changes. First-quarter EBITDA was $149.4 million, and EBITDA margin was 21.1%, nearly in line with 21.2% in the year-ago period.
That stability came despite elevated reimbursed out-of-pocket activity. Pass-throughs were roughly 44% of revenues in the quarter, creating mix noise that can make reported growth and booking comparisons harder to read.
Execution is becoming as important as volume. Improved employee retention, operating discipline and a centralized full-service platform give Medpace tools to defend margins while demand patterns normalize.
Charles River Laboratories International, Inc. (CRL - Free Report) gives investors another angle on outsourced research demand. Its preclinical and drug-development services sit earlier in the development chain, so its trends can complement what Phase I-IV focused companies reveal about clinical activity.
MEDP AI Spending Raises a Near-Term QuestionMedpace’s technology investment adds another layer to the 2026 growth debate. Artificial intelligence spending is expected to exceed savings through 2026-2027, limiting the near-term productivity benefit.
That does not make the spending unimportant. It shows how healthcare-services companies may need to absorb upfront technology costs before automation, analytics or workflow improvements show up in margins.
For investors, the question is timing. AI can support better execution over time, but the current setup points to expense absorption before measurable operating leverage.
Medpace Scores Reflect Growth With RestraintThe bottom line is that Medpace sits in a healthier position than its softer booking signals suggest, but the trend picture still requires patience. Backlog conversion, metabolic exposure and durable margins support the story, while cancellations, longer start times and AI spending keep the near-term setup measured.
Image Source: Zacks Investment Research
The stock currently carries a Zacks Rank #3 (Hold). That indicates a more balanced short-term earnings-revision profile rather than a clear positive or negative signal. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Medpace’s Style Scores sharpen that view. Its Growth Score of A points to attractive growth characteristics, while its Momentum Score of C is more neutral and its Value Score of D signals less obvious valuation support. The VGM Score of B suggests the broader style profile remains constructive, but not enough by itself to override the more restrained Zacks Rank #3 signal.
Key Takeaways Medpace's $2.93B backlog supports revenue visibility, with $1.9B-$1.94B expected to convert over 12 months.MEDP's metabolic programs help stabilize backlog as oncology and cardiovascular see higher cancellations.MEDP faces softer proposal activity and a 0.88X book-to-bill ratio, tempering near-term growth signals. Medpace Holdings, Inc. (MEDP - Free Report) has a near-term setup defined less by headline growth and more by the quality of its backlog. Revenue visibility remains meaningful, but booking momentum is not yet sending a clean reacceleration signal.
The company still has several supports, including stable margins, liquidity and metabolic demand. The issue for investors is whether cancellations and softer requests for proposals keep that visibility from turning into faster growth.
Here’s a look at Medpace’s stock performance over the past 12 months.
Image Source: Zacks Investment Research
How Medpace Makes Its Clinical Model WorkMedpace operates as a global, full-service clinical contract research organization supporting Phase I-IV drug and device development. Its services include protocol and project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance, submission support, bioanalytical labs and medical imaging.
The model is centralized and managed as one full-service platform, which helps keep study execution consistent across North America, Europe and Asia. Medpace has particular depth in oncology, metabolic disease, cardiology, central nervous system, antiviral and anti-infective work.
Client mix is another defining feature. Small biopharma accounted for 82% of fiscal 2025 revenues, while mid-sized biopharma represented 13%, leaving MEDP closely tied to emerging and development-stage sponsors.
IQVIA Holdings Inc. (IQV - Free Report) gives investors another large-scale CRO reference point because it provides clinical research services, commercial insights and healthcare intelligence to life sciences customers. Charles River Laboratories International, Inc. (CRL - Free Report) sits in an adjacent contract research area, with drug discovery, non-clinical development and safety testing exposure.
MEDP Backlog Still Supports 2026 RevenueBacklog remains the clearest source of revenue continuity. Medpace ended March 31, 2026, with backlog of $2.93 billion, up 2.9% from the year-ago period.
Management projects roughly $1.9 billion-$1.94 billion of backlog will convert into revenues over the next 12 months. That conversion base gives the company a bridge into 2026 even as net new business awards of $618.4 million produced a net book-to-bill ratio of 0.88X in the first quarter.
The distinction matters. Backlog supports visibility, but a sub-1.0X book-to-bill means awards did not fully replenish quarterly revenues. For now, the backlog points to continuity rather than proof that growth is ready to accelerate.
Take a look at Medpace’s sales multiple over the last five years.
Image Source: Zacks Investment Research
Medpace Finds Stability in Metabolic DemandMetabolic and GLP-1 programs remain an important stabilizer. These programs have historically carried lower cancellation rates than some other tracked therapeutic areas, which supports backlog quality and utilization.
That exposure is valuable because oncology and cardiovascular programs have been more cancellation-prone. In the first quarter of 2026, metabolic revenues reached $237.6 million, exceeding oncology revenues of $201.2 million and making metabolic the largest disclosed therapeutic area by revenue.
The opportunity is not without limits. New metabolic opportunities could face saturation or price sensitivity, but durable in-flight work still helps MEDP absorb pressure elsewhere in the portfolio.
MEDP Faces the Drag From CancellationsCancellations remain the main offset to the backlog story. First-quarter cancellations reached their highest level in more than a year, with oncology and cardiovascular programs the largest contributors.
The demand funnel also looks uneven. Requests for proposals declined sequentially and year over year, while the first-quarter book-to-bill ratio stayed below 1.0X.
Initial award notifications and win rates were stronger, which helps the pipeline narrative. Still, many awards remain in pre-backlog, and typical lags of three to five quarters before program starts limit the immediate revenue benefit.
Medpace Signals Matter for Patient InvestorsThe bottom line is that MEDP offers a balanced signal set. Backlog conversion, stable profitability and metabolic exposure support patience, but cancellations, softer proposal activity and delayed program starts keep the near-term outlook measured.
The stock currently carries a Zacks Rank #3 (Hold), which points to more balanced short-term earnings estimate picture. Its Style Scores show a Growth Score of A, Value Score of D, Momentum Score of C and VGM Score of B. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
That mix fits the current debate. The Growth Score of A and VGM Score of B point to attractive growth traits and a favorable combined style profile, while the Value Score of D suggests valuation support is less clear. For investors, MEDP’s next signal is likely to come from whether backlog quality and awards can outpace cancellations without pressuring margins.
Medpace (MEDP - Free Report) closed the most recent trading day at $543.57, moving +2.64% from the previous trading session. The stock's change was more than the S&P 500's daily loss of 0.22%. At the same time, the Dow lost 0.03%, and the tech-heavy Nasdaq lost 0.66%.
Shares of the provider of outsourced clinical development services witnessed a gain of 18.85% over the previous month, beating the performance of the Medical sector with its gain of 6.47%, and the S&P 500's loss of 1.21%.
Market participants will be closely following the financial results of Medpace in its upcoming release. The company plans to announce its earnings on July 22, 2026. In that report, analysts expect Medpace to post earnings of $4.08 per share. This would mark year-over-year growth of 31.61%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $678.51 million, up 12.47% from the year-ago period.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $17.04 per share and revenue of $2.79 billion, indicating changes of +11.52% and +10.32%, respectively, compared to the previous year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Medpace. Such recent modifications usually signify the changing landscape of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. At present, Medpace boasts a Zacks Rank of #3 (Hold).
Investors should also note Medpace's current valuation metrics, including its Forward P/E ratio of 31.08. This denotes a premium relative to the industry average Forward P/E of 15.95.
Also, we should mention that MEDP has a PEG ratio of 2.69. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. As the market closed yesterday, the Medical Services industry was having an average PEG ratio of 1.39.
The Medical Services industry is part of the Medical sector. This group has a Zacks Industry Rank of 95, putting it in the top 39% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
Investors looking for stocks in the Medical Services sector might want to consider either Concentra Group (CON) or Medpace (MEDP). But which of these two stocks offers value investors a better bang for their buck right now?
In the latest close session, Medpace (MEDP - Free Report) was up +1.4% at $519.96. The stock outpaced the S&P 500's daily loss of 0.01%. On the other hand, the Dow registered a gain of 0.14%, and the technology-centric Nasdaq decreased by 0.46%.
Shares of the provider of outsourced clinical development services have appreciated by 19.81% over the course of the past month, outperforming the Medical sector's gain of 2.92%, and the S&P 500's loss of 1.4%.
The investment community will be closely monitoring the performance of Medpace in its forthcoming earnings report. The company is scheduled to release its earnings on July 22, 2026. It is anticipated that the company will report an EPS of $4.08, marking a 31.61% rise compared to the same quarter of the previous year. At the same time, our most recent consensus estimate is projecting a revenue of $678.51 million, reflecting a 12.47% rise from the equivalent quarter last year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $17.04 per share and a revenue of $2.79 billion, signifying shifts of +11.52% and +10.32%, respectively, from the last year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Medpace. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Right now, Medpace possesses a Zacks Rank of #2 (Buy).
Looking at its valuation, Medpace is holding a Forward P/E ratio of 30.09. This valuation marks a premium compared to its industry average Forward P/E of 15.24.
Meanwhile, MEDP's PEG ratio is currently 2.6. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. Medical Services stocks are, on average, holding a PEG ratio of 1.4 based on yesterday's closing prices.
The Medical Services industry is part of the Medical sector. This group has a Zacks Industry Rank of 95, putting it in the top 39% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
On June 23, 2026, Medpace Holdings Inc MEDP shares rose 3.9% today, closing at $473.53. The stock has experienced a 52-week range of $305.69 to $628.92, reflecting significant volatility over the past year.
GF Value™ verdict: The current price is $473.53, which is 5.8% below the GF Value™ of $502.42.GF Score™: Medpace has a strong GF Score™ of 98/100, indicating robust fundamentals across various dimensions.Most notable signal: The momentum rank is 8/10, suggesting positive price movement trends. Is MEDP Overvalued or Undervalued? Based on the GF Value™ analysis, Medpace Holdings Inc MEDP is considered undervalued at its current price of $473.53, which reflects a 5.8% downside from the intrinsic value estimated at $502.42. This margin of safety suggests a potential buying opportunity for investors willing to accept the inherent risks associated with market fluctuations. The GF Valuation label indicates that the stock is fairly valued, which means that while it may present an opportunity, investors should remain cautious about external market pressures and overall economic conditions. GF Value™ is GuruFocus' proprietary measure of intrinsic value, calculated from historical trading multiples, past business growth, and future performance estimates.
How Does MEDP's Valuation Compare to Its History? Metric Current Historical P/E (TTM) 29.8x 31.4x Forward P/E 27.9x N/A The current P/E ratio of 29.8x is 5% below its 5-year median P/E of 31.4x, indicating that the stock is trading below its historical valuation levels. This P/E analysis aligns with the GF Value™ verdict, supporting the notion that MEDP is undervalued and may present a favorable investment opportunity, provided that other financial metrics continue to perform well.
What Does MEDP's GF Score™ Tell Us? Metric Rating GF Score™ 98 Financial Strength 6/10 Profitability 10/10 Growth 10/10 Valuation 10/10 Momentum 8/10 Medpace's high GF Score™ of 98/100 emphasizes its strong fundamentals, particularly in Profitability and Growth, both rated 10/10. This suggests a solid operational performance and potential for future expansion. However, the Financial Strength rating of 6/10 indicates some caution, as it may suggest a moderate level of risk in terms of financial stability. Overall, the strong scores in Profitability, Growth, and Valuation highlight the company’s robust potential, although the financial strength aspect warrants closer scrutiny.
What Are Insiders Doing with MEDP Stock? In the last three months, Medpace insiders sold a total of $7.4 million in shares, indicating a lack of buying activity during this period. This pattern may suggest that insiders are not currently optimistic about the stock's short-term performance, which could point towards caution for outside investors. However, it is important to note that insider selling does not always indicate negative sentiment, as it may also be a strategy for personal financial management or tax purposes.
What This Means for Investors Based on the analysis of GF Value™, Medpace Holdings Inc MEDP is currently undervalued, presenting a potential opportunity for investors looking for stocks with solid fundamentals and growth potential. Nonetheless, caution is advised due to the recent insider selling and market volatility.
For the complete analysis, visit the Medpace Holdings Inc MEDP stock page. You can also explore the GF Value™ page for detailed valuation methodology, or use the GuruFocus Stock Screener to find similar opportunities.
Frequently Asked Questions What is MEDP's GF Score™?
Medpace's GF Score™ is 98/100, indicating strong fundamentals and a high likelihood of generating long-term returns based on historical data.
Is MEDP overvalued or undervalued?
MEDP is currently considered undervalued, with a GF Value™ of $502.42 compared to its current price of $473.53.
What is MEDP's P/E ratio?
MEDP's P/E ratio (TTM) is 29.8x, which is below its 5-year median P/E of 31.4x, indicating that the stock is trading at a lower valuation compared to its historical averages.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will report its second quarter 2026 financial results after the market close on Wednesday, July 22, 2026. The Company will host a conference call the following morning, Thursday, July 23, 2026, at 9:00 a.m. ET to discuss these results.
To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended you join 10 minutes prior to the event start. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique PIN that can be used to access the call.
To access the conference call via webcast, visit the “Investors” section of Medpace’s website at investor.medpace.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.
A supplemental slide presentation will also be available at the “Investors” section of Medpace’s website prior to the start of the call.
About Medpace
Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace’s mission is to accelerate the global development of safe and effective medical therapeutics through its high-science and disciplined operating approach that leverages regulatory and therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system and anti-viral and anti-infective. Headquartered in Cincinnati, Ohio, Medpace employs approximately 6,300 people across 46 countries as of March 31, 2026.
Medpace (MEDP - Free Report) closed the most recent trading day at $461.60, moving -1.26% from the previous trading session. The stock trailed the S&P 500, which registered a daily loss of 0.57%. Meanwhile, the Dow experienced a rise of 0.64%, and the technology-dominated Nasdaq saw a decrease of 1.15%.
The provider of outsourced clinical development services's stock has climbed by 11.13% in the past month, exceeding the Medical sector's gain of 4.28% and the S&P 500's gain of 2.14%.
The investment community will be paying close attention to the earnings performance of Medpace in its upcoming release. The company's earnings per share (EPS) are projected to be $4.08, reflecting a 31.61% increase from the same quarter last year. Our most recent consensus estimate is calling for quarterly revenue of $678.51 million, up 12.47% from the year-ago period.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $17.04 per share and a revenue of $2.79 billion, indicating changes of +11.52% and +10.32%, respectively, from the former year.
Investors should also note any recent changes to analyst estimates for Medpace. These revisions typically reflect the latest short-term business trends, which can change frequently. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. Medpace is currently sporting a Zacks Rank of #3 (Hold).
Investors should also note Medpace's current valuation metrics, including its Forward P/E ratio of 27.44. For comparison, its industry has an average Forward P/E of 15.69, which means Medpace is trading at a premium to the group.
Also, we should mention that MEDP has a PEG ratio of 2.37. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Medical Services industry had an average PEG ratio of 1.44 as trading concluded yesterday.
The Medical Services industry is part of the Medical sector. This group has a Zacks Industry Rank of 109, putting it in the top 45% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
New York, New York--(Newsfile Corp. - June 5, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Medpace Holdings, Inc. (NASDAQ: MEDP) and certain of its officers.
This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Medpace securities between April 22, 2025 and February 9, 2026, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: bgandg.com/MEDP.
Medpace Case Details
The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose that:
Medpace's public statements regarding its expected book-to-bill ratio for the fourth quarter and second half of fiscal year 2025 lacked a reasonable basis; Defendants repeatedly portrayed an overly optimistic book-to-bill ratio of approximately 1.15 during earnings calls and other public communications, despite contrary internal information; and as a result, Defendants' statements about the Company's business, operations, and financial prospects were materially false and misleading at all relevant times.What's Next for Medpace Investors?
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm's site: bgandg.com/MEDP, or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 917-590-0911. If you suffered a loss in Medpace you have until June 5, 2026, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.
No Cost to Medpace Investors
We, Bronstein, Gewirtz & Grossman LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman, LLC for Medpace Securities Class Action?
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide. More at www.bgandg.com.
"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.
Follow us for updates on LinkedIn, X, Facebook, or Instagram.
Attorney advertising.
Prior results do not guarantee similar outcomes.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/294775
Source: Bronstein, Gewirtz & Grossman, LLC
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
New York, New York--(Newsfile Corp. - June 5, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Medpace Holdings, Inc. (NASDAQ: MEDP) between April 22, 2025 and February 9, 2026, inclusive (the "Class Period"), of the important June 8, 2026 lead plaintiff deadline.
SO WHAT: If you purchased Medpace common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
WHAT TO DO: To join the Medpace class action, go to https://rosenlegal.com/submit-form/?case_id=58453 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 8, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or concealed material adverse facts concerning the true state of Medpace's backlog cancellation rate. In fact, defendants continuously touted "well behaved" cancellation rates. Furthermore, Medpace made clear that cancellations were not caused by weak business or a weak funding environment, providing investors with overly positive growth expectations that could not maintain the projected 1.15 book-to-bill ratio. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Medpace class action, go to https://rosenlegal.com/submit-form/?case_id=58453 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
-------------------------------
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/300348
Source: The Rosen Law Firm PA
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors about a class action lawsuit on behalf of purchasers of common stock of Medpace Holdings, Inc. (NASDAQ: MEDP) between April 22, 2025 and February 9, 2026. Medpace describes itself as a “clinical contract research organization (CRO) focused on providing scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries.”
For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653.
The Allegations: Rosen Law Firm is Investigating the Allegations that Medpace Holdings, Inc. (NASDAQ: MEDP) Misled Investors Regarding its Business Operations.
According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or concealed material adverse facts concerning the true state of Medpace’s backlog cancellation rate. In fact, defendants continuously touted “well behaved” cancellation rates. Furthermore, Medpace made clear that cancellations were not caused by weak business or a weak funding environment, providing investors with overly positive growth expectations that could not maintain the projected 1.15 book-to-bill ratio. When the true details entered the market, the lawsuit claims that investors suffered damages.
What Now: You may be eligible to participate in the class action against Medpace Holdings, Inc. Shareholders who want to serve as lead plaintiff for the class must file their motions with the court by June 8, 2026. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
About Rosen Law Firm: Some law firms issuing releases about this matter do not actually litigate securities class actions. Rosen Law Firm does. Rosen Law Firm is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses, improving corporate governance structures, and holding company executives accountable for their wrongdoing. Since its inception, Rosen Law Firm has obtained over $1 billion for shareholders.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
, /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Medpace Holdings, Inc. ("Medpace" or the "Company") (NASDAQ: MEDP).
IF YOU SUFFERED A LOSS ON YOUR MEDPACE INVESTMENTS, CLICK HERE BEFORE JUNE 8, 2026 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT
What Is The Lawsuit About?
The complaint filed alleges that, between April 22, 2025 and February 9, 2026, Defendants: (1) consistently oversold the Company's projected book-to-bill ratio for fourth quarter 2025; (2) knew or recklessly disregarded the impact that cancellations have on the Company's book-to-bill ratio; (3) frequently claimed that the projection of a 1.15 book-to-bill ratio for fourth quarter 2025 was reasonable and achievable and that cancellations were not a sign of a weak business environment; (4) reassured investors that the Company was not concerned about the lack of diversity in its pre-backlog; (5) stated that, despite the uptick in metabolic growth, the Company's upside was broad-based and not isolated to any handful of studies; and (6) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.
Contact Us To Participate or Learn More:
If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us.
Charles Linehan, Esq.,
Glancy Prongay Wolke & Rotter LLP,
1925 Century Park East, Suite 2100,
Los Angeles California 90067
Email: [email protected]
Telephone: 310-201-9150 (Toll-Free: 888-773-9224)
Visit our website at www.glancylaw.com.
Follow us for updates on LinkedIn, Twitter, or Facebook.
If you inquire by email, please include your mailing address, telephone number and number of shares purchased.
To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contact Us:
Glancy Prongay Wolke & Rotter LLP,
1925 Century Park East, Suite 2100,
Los Angeles, CA 90067
Charles Linehan
Email: [email protected]
Telephone: 310-201-9150
Toll-Free: 888-773-9224
Visit our website at: www.glancylaw.com.
